A Multi-center, Phase 2 Study Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC in Combination With tPA, Mechanical Thrombectomy or Both in Moderate to Severe Acute Ischemic Stroke
Phase: PHASE2
Conditions: Ischemic Stroke
Sponsor: ZZ Biotech, LLC

STUDY OFFICIAL TITLE:  ZZ-3K3A-201: A multi-center, Phase 2 
study using a continual reassessment method to determine the safety 
and tolerability of 3K3A-APC, a recombinant variant of human 
activated protein C (APC), in combination with tissue plasminogen 
activator (tPA), mechanical thrombectomy or both in moderate to 
severe acute ischemic stroke.  
NCT#: NCT02222714 
VERSION DATE OF DOCUMENT: 07-October-2016 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 1 of 81 
 
FULL PROTOCOL TITLE 
ZZ-3K3A-201: A multi-center, Phase 2 study using a continual reassessment method to 
determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated 
protein C (APC), in combination with tissue plasminogen activator (tPA), mechanical 
thrombectomy or both in moderate to severe acute ischemic stroke.  
 
Protocol Version: 8.1  
Protocol Date:  7-Oct-2016 
NeuroNEXT Protocol Number: NN104 
 
 
SHORT PROTOCOL TITLE 
RHAPSODY: Safety evaluation of 3K3A-APC in ischemic stroke 
 
 
Protocol Principal Investigator (PPI): 
Patrick D. Lyden, MD, FAAN, FAHA 
Chairman, Department of Neurology 
Cedars-Sinai Medical Center 
8700 Beverly Blvd, AHSP 6417 
Los Angeles, CA 90048 
 
Email: patrick.lyden@cshs.org 
 
Protocol Co-Investigator (Co-I): 
Berislav V. Zlokovic, M.D., Ph.D. 
Director, Zilkha Neurogenetic Institute 
Keck School of Medicine 
University of Southern California 
1501 San Pablo Street, ZNI 301 
Los Angeles, CA 90089 
 
 
Supported by: 
The National Institute of Neurological Disorders and Stroke (NINDS) 
Cedars-Sinai: 1U01NS088312-01; Clinical Coordinating Center (CCC): U01NS77179-01; Data 
Coordinating Center (DCC): U01NS077352 
 
Study Intervention Provided by: 
ZZ Biotech, LLC 
1001 McKinney, Suite 1900 
Houston, TX 77002 
 
 
Sponsor of IND/IDE: 
ZZ Biotech, LLC 
1001 McKinney, Suite 1900 
Houston, TX 77002 
 
 
IND  #103,728 
 
The information contained herein is confidential and proprietary in nature, and will not be disclosed 
to any third party without written approval of authorized designee.  This document may be disclosed 
to the appropriate institutional review boards or to duly authorized representatives of the US Food 
and Drug Administration or a national regulatory authority under the condition that they maintain 
confidentiality. 
 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 2 of 81 
INVESTIGATOR AGREEMENT ...................................................................................................... 5 
SYNOPSIS .................................................................................................................................... 11 
1 
STUDY OBJECTIVES .......................................................................................................... 18 
1.1 
Primary Objectives ................................................................................................... 18 
1.2 
Secondary Objectives .............................................................................................. 18 
1.3 
Exploratory Objectives ............................................................................................. 18 
2 
BACKGROUND .................................................................................................................... 18 
2.1 
Ischemic Stroke ........................................................................................................ 18 
2.2 
Current Treatment for Stroke ................................................................................... 19 
2.3 
Study Drug: 3K3A-APC ............................................................................................ 20 
2.3.1 
Rationale for APC in Treating Stroke ....................................................................... 21 
2.3.2 
Rationale for use of APC following tPA or Mechanical Thrombectomy ................... 22 
2.3.3 
Recombinant Human APC (drotrecogin alfa [activated], Xigris®) ............................ 24 
2.4 
Nonclinical Studies of 3K3A-APC............................................................................. 24 
2.4.1 
Efficacy in Animal Models of Stroke ......................................................................... 24 
2.4.2 
Toxicology Studies ................................................................................................... 26 
2.5 
Clinical Studies of 3K3A-APC .................................................................................. 26 
2.6 
Rationale for Dose Selection .................................................................................... 28 
3 
STUDY DESIGN ................................................................................................................... 28 
3.1 
Study Design and Enrollment: .................................................................................. 28 
3.1.1 
Dose Limiting Toxicities: ........................................................................................... 30 
3.1.2 
Safety Review Committee: ....................................................................................... 31 
3.1.3 
Data Monitoring and Data Safety Monitoring Board:................................................ 31 
4 
SELECTION AND ENROLLMENT OF SUBJECTS ............................................................. 32 
4.1 
Inclusion Criteria ....................................................................................................... 32 
4.2 
Exclusion Criteria...................................................................................................... 32 
4.3 
Subject Discontinuation ............................................................................................ 33 
4.3.1 
Subject Withdrawal Criteria ...................................................................................... 33 
4.3.2 
Discontinuation of Study Drug .................................................................................. 34 
4.4 
Study Enrollment Procedures ................................................................................... 34 
4.4.1 
Subject Recruitment and Retention ......................................................................... 34 
4.4.2 
Reporting of Screening Data .................................................................................... 34 
4.4.3 
Informed Consent ..................................................................................................... 35 
4.4.4 
Randomization/Treatment Assignment .................................................................... 35 
5 
STUDY DRUG ...................................................................................................................... 36 
5.1 
Description, Packaging, Supply and Labeling .......................................................... 36 
5.1.1 
3K3A-APC ................................................................................................................ 36 
5.1.2 
Placebo ..................................................................................................................... 37 
5.2 
Storage of Study Drug .............................................................................................. 37 
5.3 
Preparation and Blinding of Study Drug ................................................................... 37 
5.4 
Administration of Study Drug .................................................................................... 38 
5.5 
Accountability of Study Drug .................................................................................... 38 
5.5.1 
Required Concomitant Medications/Interventions .................................................... 39 
5.5.2 
Prohibited Medications and Interventions ................................................................ 40 
6 
STUDY PROCEDURES ....................................................................................................... 41 
6.1 
Schedule of Activities ............................................................................................... 41 
6.2 
Schedule of Activities: Study Drug Infusion Detail ................................................... 45 
6.3 
Timing of Study Activities ......................................................................................... 48 
6.3.1 
Screening/Pre-Randomization Evaluations/procedures .......................................... 48 
6.3.1.1.1 
Admission/Standard of Care Procedures ................................................... 48 
6.3.1.2 
Informed Consent ............................................................................................ 49 
6.3.1.3 
Slot Assignment and Randomization .............................................................. 49 
6.3.2 
On-Study Evaluations/procedures............................................................................ 49 
6.3.2.1.1 
Study-Specific Baseline Procedures .......................................................... 49 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 3 of 81 
6.3.2.1.2 
Study-Specific Post-Treatment Procedures ............................................... 50 
6.3.2.1.3 
Study-Specific Daily Procedures, Days 2-6 ............................................... 51 
6.3.2.1.4 
Study-Specific Procedures, Day 7 or Discharge (+/- 3 day window) ......... 52 
6.3.2.1.5 
Study-Specific Procedures, Day 14 (+/- 4 day window)............................. 52 
6.3.2.2 
Study-Specific Procedures, Day 30 (+/- 5 day window) .................................. 52 
6.3.2.3 
Study-Specific Procedures, Day 90 (+/- 10 day window) ................................ 53 
6.4 
Special Instructions and Definitions of Evaluations.................................................. 53 
6.4.1 
Protocol Deviations and Violations ........................................................................... 53 
6.4.2 
Medical History ......................................................................................................... 54 
6.4.3 
Treatment History ..................................................................................................... 54 
6.4.4 
Concomitant Medications/Treatments ...................................................................... 54 
6.4.5 
Discharge Medications ............................................................................................. 54 
6.4.6 
Protocol Amendments and Study Termination ......................................................... 54 
6.4.7 
Special Blood Sample Collection and Handling ....................................................... 54 
6.4.7.1 
Pharmacokinetic Sample Collection and Handling (Plasma) .......................... 54 
6.4.7.2 
Blood Sample Collection and Handling for Antibody Testing (Serum) ........... 55 
6.4.8 
Questionnaire Certification ....................................................................................... 56 
6.4.9 
Imaging Central Review ........................................................................................... 56 
7 
MANAGEMENT OF ADVERSE EXPERIENCES ................................................................. 56 
8 
STATISTICAL CONSIDERATIONS ...................................................................................... 58 
8.1 
General Design Issues ............................................................................................. 58 
8.1.1 
Summary of Study Design ........................................................................................ 58 
8.1.2 
Randomization and Blinding ..................................................................................... 60 
8.2 
Outcomes ................................................................................................................. 61 
8.2.1 
Primary Outcome (Including Definition) ................................................................... 61 
8.2.2 
Secondary Outcome(s) ............................................................................................ 62 
8.3 
Sample Size and Accrual ......................................................................................... 63 
8.3.1 
Primary Outcome...................................................................................................... 63 
8.3.2 
Secondary Outcome (Bleed Rates).......................................................................... 65 
8.4 
Data Monitoring ........................................................................................................ 66 
8.5 
Data Analyses .......................................................................................................... 67 
8.5.1 
Primary Objective ..................................................................................................... 67 
8.5.2 
Secondary Objectives .............................................................................................. 67 
9 
DATA COLLECTION, SITE MONITORING, AND ADVERSE EXPERIENCE REPORTING 68 
9.1 
Data Management .................................................................................................... 68 
9.1.1 
Enrollment Registration ............................................................................................ 68 
9.1.2 
Data Entry ................................................................................................................. 69 
9.2 
Role of Data Management ....................................................................................... 69 
9.3 
Quality Assurance .................................................................................................... 69 
9.3.1 
Development of Monitoring Plan .............................................................................. 70 
9.3.2 
Site Monitoring Visits ................................................................................................ 70 
9.3.3 
Laboratory Data Flow ............................................................................................... 70 
9.4 
Adverse Experience Reporting ................................................................................. 71 
9.4.1 
Definitions of Adverse Events, Suspected Adverse Drug Reactions & Serious 
Adverse Events ........................................................................................................ 72 
9.4.1.1 
Adverse Event and Suspected Adverse Drug Reactions ............................... 72 
9.4.1.2 
Serious Adverse Events .................................................................................. 73 
9.4.1.3 
Neuroworsening .............................................................................................. 74 
9.4.1.4 
Symptomatic Intracranial Hemorrhage (SICH) ............................................... 74 
9.4.1.5 
Assessment and Recording of Adverse Events .............................................. 74 
9.4.1.6 
Breaking the Study Blind ................................................................................. 76 
10 
HUMAN SUBJECTS ............................................................................................................. 77 
10.1 
Central Institutional Review Board (CIRB) Review and Informed Consent ............. 77 
10.2 
Subject Confidentiality .............................................................................................. 77 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 4 of 81 
10.3 
Study Modification/Discontinuation .......................................................................... 77 
11 
PUBLICATION OF RESEARCH FINDINGS ......................................................................... 77 
12 
REFERENCES ..................................................................................................................... 78 
 
 
 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 5 of 81 
INVESTIGATOR AGREEMENT 
 
I have read the foregoing protocol, ZZ-3K3A-201, and agree to conduct the study as described 
herein. I will provide copies of this protocol and all pertinent information to the study personnel 
under my supervision. I will discuss this material with them and ensure they are fully informed 
regarding the investigational plan and the conduct of the study according to 21 CFR parts 50, 54, 
56 and 812, ICH Good Clinical Practices Guidelines and Institutional Review Board (IRB) 
requirements. 
NOTE: By signing the protocol, the Investigator agrees to keep all information provided by the 
NeuroNEXT Network in strict confidence and to request the same from his/her staff and the 
Institutional Review Board. Study documents provided by the NeuroNEXT Network will be stored 
appropriately to ensure their confidentiality. The Investigator should not disclose such information 
to others without authorization, except to the extent necessary to conduct the study.  
 
 
 
 
 
______________________________________ 
_______________________ 
Investigator Signature 
Date 
 
______________________________________ 
Print Investigator’s Name 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 7 of 81 
LIST OF ACRONYMS, ABBREVIATIONS, AND DEFINITIONS OF TERMS 
Abbreviation 
Term 
ACA 
anterior cerebral artery 
ADA 
anti-drug antibody 
AE 
adverse event 
AMI 
acute myocardial infarction 
APC 
activated protein C 
aPTT 
activated partial thromboplastin time (same as PTT) 
ASPECTS 
Alberta stroke program early CT score 
AUC0-inf 
area under the plasma concentration-time curve from time 0 extrapolated 
to infinity 
AVM 
arterio-venous malformation 
BBB 
blood brain barrier 
βHCG 
beta human chorionic gonadotropin 
BI 
Barthel Index 
BMI 
body mass index  
C 
centigrade 
CBC 
complete blood count 
CCC 
Clinical Coordination Center 
CDE 
Common Data Elements 
CHO 
Chinese hamster ovary 
CL 
total clearance 
cm 
centimeters 
Cmax 
maximum observed plasma concentration 
CFR 
Code of Federal Regulations 
CIRB 
Central Institutional Review Board 
Con Med 
concomitant medication 
CRF 
Case Report Form 
CRM 
continual reassessment method 
CS 
clinically significant 
Css 
Steady-state concentration 
CSS 
clinical study site 
CSS PI 
clinical study site Principal Investigator 
CT 
computed tomography or computed tomography scan 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 8 of 81 
Abbreviation 
Term 
CTCAE 
Common Terminology Criteria for Adverse Events 
DCC 
Data Coordination Center 
dL 
deciliter 
DLT 
dose-limiting toxicity 
DM 
data management 
DSMB 
Data Safety Monitoring Board 
DWI 
diffusion-weighted imaging 
ECG 
electrocardiogram 
ECL 
electrochemoluminescence ligand  
eCRF 
electronic case report form 
EDC 
electronic data capture 
EOI 
end of infusion 
EPCR 
endothelial protein C receptor 
ER 
emergency room 
FDA 
Food and Drug Administration 
g 
grams 
GCP 
Good Clinical Practice 
GFR 
glomerular filtration rate 
GRE 
gradient recalled echo 
HED 
human equivalent dose 
Hg 
mercury 
HIPAA 
Health Insurance Portability and Accountability Act 
IA 
intra-arterial 
ICA 
internal carotid artery 
ICF 
Informed Consent Form  
ICH 
International Conference on Harmonization 
IMM 
Independent Medical Monitor 
IMP 
Investigational Medicinal Product (refers to both active drug and placebo) 
IND 
Investigational New Drug  
INR 
International Normalized Ratio 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
IV 
intravenous 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 9 of 81 
Abbreviation 
Term 
IWRS 
interactive web response system 
kg 
kilogram 
L 
liter 
m 
meter 
M1 
sphenoidal segment of middle cerebral artery 
M2 
insular segment of middle cerebral artery 
mAOL 
modified arterial occlusive lesion 
MCA 
middle cerebral artery 
MCAO 
middle cerebral artery occlusion 
MedDRA 
Medical Dictionary for Regulatory Activities 
mEq 
milliequivalent 
mg 
milligram 
mL 
milliliter 
mm 
millimeter 
MRI 
magnetic resonance imaging 
mRS 
modified Rankin Scale 
MTD 
maximum tolerated dose 
MTL 
minimum toxicity level 
NCI 
National Cancer Institute 
NCS 
Not clinically significant 
NIHSS 
National Institutes of Health Stroke Scale 
NINDS 
National Institute of Neurological Disorders and Stroke 
NOAEL 
no observed adverse effect level 
PAR1 
protease activated receptor 1 
PE 
physical examination 
PK 
pharmacokinetic 
PPI 
Protocol Principal Investigator 
PSC 
Protocol Steering Committee 
PTT 
partial thromboplastin time (see aPTT) 
PT 
prothrombin time 
rt-PA 
recombinant tissue plasminogen activator 
rwt 
recombinant wild-type 
SAE 
serious adverse event 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 10 of 81 
Abbreviation 
Term 
SICH 
symptomatic intracranial hemorrhage 
SID 
subject identification number 
SOA 
schedule of activities 
SOC 
standard of care 
SRC 
Safety Review Committee 
SWI 
susceptibility weighted imaging 
t1/2 
elimination half-life 
TBD 
to be determined 
TICI 
thrombolysis in cerebral infarction 
Tmax 
time at which the maximum plasma concentration was observed 
tPA 
recombinant tissue plasminogen activator 
ULN 
upper limit of normal 
US 
United States 
USP 
United States Pharmacopeia 
VS 
vital signs 
Vz 
volume of distribution 
WNL 
within normal limits 
wt 
wild-type 
µg 
microgram 
λz 
elimination rate constant 
 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 11 of 81 
SYNOPSIS 
Investigational Product 
3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC) in which 3 lysine residues 
(191-193) of the 37-loop are replaced by 3 alanine residues. 
 
Study Title 
ZZ-3K3A-201: A multi-center, Phase 2 study using a continual reassessment method to determine 
the safety and tolerability of 3K3A-APC, a Recombinant Variant of Human Activated Protein C 
(APC), in combination with tissue plasminogen activator (tPA), mechanical thrombectomy or both 
in moderate to severe acute ischemic stroke. 
 
Objectives 
Primary: 
• 
To evaluate the safety of multiple ascending intravenous (IV) doses of 3K3A-APC following 
recombinant tissue plasminogen activator (tPA) administration or mechanical thrombectomy or 
both in subjects who have experienced moderate to severe acute ischemic stroke. 
Secondary: 
• 
To investigate the pharmacokinetic (PK) properties of 3K3A-APC following tPA or mechanical 
thrombectomy or both in adults with acute ischemic stroke. 
• 
To evaluate the effect of 3K3A-APC on the presence of tPA/mechanical thrombectomy-related 
bleeding (hemorrhage and microbleeds) in the brain as determined by MRI at Day 30. 
Exploratory: 
• 
To evaluate the effect of 3K3A-APC on the volume of tPA/mechanical thrombectomy-related 
bleeding (hemorrhage and microbleeds) in the brain as determined by MRI at Day 30. 
• 
To evaluate the effect of 3K3A-APC on incidence of subarachnoid hemorrhage in subjects who 
receive mechanical thrombectomy. 
• 
To collect the 7-day National Institutes of Health Stroke Scale (NIHSS) scores as a predictor 
for 90-day modified Rankin Scale (mRS). 
• 
To collect the 90-day mRS. 
• 
To collect the 90-day Barthel Index (BI). 
• 
To collect infarct volume at 90 days (MRI, or CT if unable to obtain MRI). 
• 
To assess the immunogenic potential of 3K3A-APC 
Design and Outcomes 
Design: 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 12 of 81 
This is a multicenter, prospective, randomized, controlled, double-blinded Phase 2 study intended 
to evaluate the safety, PK and preliminary efficacy of 3K3A-APC following administration of tPA or 
mechanical thrombectomy or both in subjects with moderate to severe acute ischemic stroke.  
Approximately 115 subjects will be randomized, which includes the planned 88 subjects in groups 
of four to either 3K3A-APC or placebo (in a 3:1 ratio) and additional placebo subjects who will be 
enrolled during safety review pauses. This study will utilize a modified version of the continual 
reassessment method (CRM) in order to establish a maximum tolerated dose (MTD)1. 
For the purposes of this study, we assume an established background symptomatic intracerebral 
hemorrhage (SICH) rate of 3-6%2-7.  Correspondingly, the MTD will be defined as the highest 
dose with a DLT rate of 10% or less.  Subjects will be enrolled to 3K3A-APC dose cohorts in 
groups of four (three to specified treatment dose and one to placebo).  Subjects will generally be 
enrolled at the dose estimated from the assumed dose-response model and prior data to be 
closest to the MTD.  However, the initial cohort will start at the lowest dose level (120 µg/kg) and 
the dose level may be escalated by no more than one dose between consecutive cohorts (there 
are no restrictions on dose level de-escalation).  Intra-subject dose modification is not permitted 
during the study. After the final group of subjects is enrolled, the final MTD will be defined as the 
highest dose with an estimated toxicity probability less than or equal to the target toxicity level of 
10%. 
The design will proceed as follows: 
• 
Enroll the first 4 subjects into cohort 1. 
o 
Treat one of the four subjects (chosen randomly) with placebo. 
o 
Treat the other three subjects with the lowest dose: 120 µg/kg. 
o 
Observe the number of subjects (out of the three treated subjects) that have a 
DLT per study definition. Any given subject who receives only one dose of study 
drug and does not experience a DLT will not be included in the CRM calculation 
(i.e. two or more doses will need to be administered to be included). 
o 
Based upon the observed information from the three treated subjects, refit the 
assumed dose-response curve. 
• 
Initially (through version 7.1. of the protocol), the re-estimated dose-response curve using 
all cohorts enrolled to date was then used to determine the highest dose level of the four 
under consideration that has an estimated probability of toxicity less than or equal to 10% 
o 
The next cohort of subjects is treated at the dose level specified above – unless 
the chosen dose level is more than one level higher than the current level.  If so, 
treat the next cohort of subjects at the next dose level above the current level. 
• 
Based on a DSMB recommendation, this process was changed as of version 8.0 of the 
protocol.  The basic process proceeds as described above, but once all subjects in a 
given cohort (n) have been enrolled, data from all prior cohorts (cohort 1, cohort 2, ….., 
cohort n-1) are used to determine the dose level of cohort n+1. 
o 
If enrollment is rapid such that both cohort (n-1) and cohort (n) are filled and 
awaiting DLT review, new subjects enrolled will be randomized to placebo until 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 13 of 81 
cohort (n-1) has been reviewed. (For example, if both cohort 13 and 14 are filled 
and awaiting review, subjects will be randomized to placebo until cohort 13 is 
closed and the model is rerun to determine the dose for cohort 15.) 
The MTD will be defined as the dose that would be chosen from the CRM at the final step.  The 
study will stop once the first of the following criteria have been met: 
• 
The maximum number of cohorts (22) has been observed. 
• 
If at any time after half of the cohorts (11) have been observed, two consecutive 
iterations suggest a 15% or higher toxicity rate at the lowest dose (stop for safety). 
• 
If the study proceeds straight to the highest dose, and then observes 9 successive 
cohorts at the highest dose with no observed toxicity (stop and declare highest dose the 
MTD).  
Outcomes and Criteria for Evaluation: 
• 
Safety - monitored by physical examinations (PEs), vital signs (VS), clinical laboratory tests 
(i.e., chemistries, hematology, coagulation studies, and urinalysis), CT and MRI, ECGs and 
adverse event (AE) assessment. 
o 
Dose-limiting toxicities will be assessed from the first dose to 48 hours following the 
last dose of study treatment (unless specified below) and defined as any of the 
following AEs that have an attribution of “related” to study treatment (possibly, 
probably, and definitely): 
▪ 
An activated partial thromboplastin time (aPTT) that reaches 2x the upper limit 
of normal (ULN) at 1 hour post-dose. Upper limit of normal range is defined 
locally by the site laboratory. 
▪ 
Symptomatic intracranial hemorrhage (SICH) defined as blood present on CT 
or MRI brain images that is associated with clinical worsening that meets the 
definition of neuroworsening (4 or more point increase in NIHSS; see section 
9.4.1.3 for definition) and in the opinion of the investigator represents a 
clinically significant change that can be attributed to the hemorrhage. 
Subarachnoid hemorrhage that occurs in subjects who receive mechanical 
thrombectomy will NOT be considered a DLT, and instead will be evaluated in 
an exploratory analysis upon study completion.   
▪ 
Findings that meet all of the following three components (Hy’s Law): 
• 
≥3 x ULN of alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST),  
• 
Serum total bilirubin (TBL) >2xULN, without initial findings of 
cholestasis (serum alkaline phosphatase (ALP) activity >2 x ULN, 
• 
And, no other reason can be found to explain the combination of 
increased aminotransferase (AT) enzymes and TBL, such as viral 
hepatitis A, B, or C, preexisting or acute liver disease, or another drug 
capable of causing the observed injury. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 14 of 81 
▪ 
Any other bleeding event classified as serious by the Investigator, or any 
bleeding that required the administration of more than 2 units of packed red 
cells over any two consecutive days. 
▪ 
Any Grade 3 laboratory value that, in the opinion of the Investigator, is related 
to study treatment. Refer to CTCAE v4.03 sections relevant to laboratory 
investigations. 
▪ 
Any adverse event that, in the opinion of the Investigator, is related to study 
treatment and leads to cessation of further dosing. 
NOTE: All suspected DLTs will be reviewed by a Safety Review Committee, and those reported 
DLTs that are considered possibly related to study drug but definitely related to another event will 
not be considered DLTs upon final adjudication. An example of such an event would be an elevated 
aPTT following dose 1 in a subject who undergoes mechanical thrombectomy during which heparin 
is administered; the elevated aPTT can be attributed to the heparin and therefore should NOT be 
considered a DLT in this isolated instance. Another example would be the occurrence of 
hypofibrinogenemia in a subject who receives tPA. Low fibrinogen levels can be attributed to tPA, 
and there is a documented rate of occurrence of 11% in subjects receiving tPA8. Furthermore, 
3K3A-APC does not cause a reduction in the level of fibrinogen in plasma and therefore this finding 
should NOT be considered a DLT. 
• 
PK analysis – blood samples will be collected from approximately 40 subjects at a sub-set of 
study sites following one of the doses of 3K3A-APC at the following time points: end of infusion 
and 20, 40, 60 and 80 minutes after the end of infusion. 
• 
Incidence of tPA/mechanical thrombectomy-related Bleeding – Day 30 MRI scans will be 
collected and evaluated by a central radiologist for the presence of hemorrhage and 
microbleeds (as defined in section 8.2.2). 
• 
Exploratory Outcomes - The study will also include outcome data typically collected in all stroke 
trials, as well as sample collection to assess the immunogenic potential of 3K3A-APC. While 
the sample size is too small to observe meaningful treatment effects, the data will allow 
confirmation that outcomes in this trial resemble previously published trials. The following will 
be collected: 
o 
Volume of bleeding (hemorrhage and microbleeds) in the brain as determined by MRI 
at Day 30 
o 
Incidence of subarachnoid hemorrhage in subjects who receive mechanical 
thrombectomy 
o 
Day 7 National Institutes of Health Stroke Scale (NIHSS) scores  
o 
Day 90 mRS 
o 
Day 90 BI 
o 
Infarct volume at 90 days (MRI, or CT if unable to obtain MRI) 
o 
Pre-dose 1, Day 14 and Day 30 anti-drug antibody samples 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 15 of 81 
 
Interventions and Duration 
Investigational or Reference Therapy, Dosage and Mode of Administration: 
3K3A-APC will be diluted in 0.9% sodium chloride in water and administered as a 100 mL IV 
infusion over 15 minutes. Four dose levels of 3K3A-APC will be considered for this study: 120, 240, 
360, and 540 µg/kg. 
Matching placebo will be 0.9% sodium chloride in water, visually indistinguishable from the test 
product.  Placebo, 100 mL, will be administered in the same manner as the active product. 
Following completion of tPA infusion or initiation of mechanical thrombectomy (arterial puncture), 
whichever is sooner, eligible adult subjects will receive 3K3A-APC or matching placebo 30 to 120 
minutes later given as a 15-minute infusion.  Subjects will receive another 15-minute infusion of 
3K3A-APC or placebo every 12 hours (+/- 1 hour) for up to 5 total infusions.  
 
Study and Treatment Duration 
Each subject will be followed for 90 days in this study.  With an expected enrollment rate of 0.3 
subjects/site/month in approximately 15 NeuroNEXT sites, it is anticipated that the study will take 
up to 28 months to enroll, which includes the observation window after each of the 22 cohorts to 
assess for DLTs. Subjects will be considered for the study after beginning tPA administration or 
mechanical thrombectomy or both for moderate to severe acute ischemic stroke.  Eligible subjects 
will receive 3K3A-APC or placebo every 12 hours for up to 5 doses (approximately 3 days), or until 
discharge from the hospital, whichever occurs first. Subjects will be monitored for safety evaluations 
through Day 7 and are expected to be seen on Days 7, 14, 30 and 90 for safety and outcome 
evaluations.   
 
Sample Size and Population 
Sample Size: 
The study will enroll approximately 115 subjects, which includes the planned 88 subjects in groups 
of four (each cohort will include one placebo and three treated subjects) and additional placebo 
subjects who will be enrolled during safety review pauses.  While placebo is not needed to 
determine the MTD, a placebo group has been included in order to conduct secondary analyses to 
examine for a reduction of tPA/mechanical thrombectomy-related bleeds by central read and to 
obtain preliminary efficacy data that may be useful for the planning of future studies. 
Randomization Scheme: 
Subjects will be randomized using an interactive web response system (IWRS) to either 3K3A-APC 
or placebo.  There are 22 groups of four subjects planned, but fewer may be enrolled should the 
study meet either of the early stopping criteria. During the DLT review periods, subjects may be 
assigned to placebo. The additional placebo subjects will be closely monitored and their enrollment 
may be discontinued should the number enrolled exceed what was planned for the study. Subjects 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 16 of 81 
will not be considered part of the intent-to-treat (ITT) cohort until they receive any amount of 3K3A-
APC or placebo.  For example, “early responders,” subjects whose symptoms resolve between 
initial randomization and initiation of IMP infusion such that they are no longer eligible (repeat 
NIHSS <5), will be removed from the study and replaced. 
Inclusion Criteria: 
1. Age 18 to 90 years, inclusive 
2. Acute ischemic stroke defined as focal, neurological deficit(s), secondary to a presumed 
vascular occlusive event 
3. Able to receive IV tPA per local standard of care, OR, begin mechanical thrombectomy 
per local standard of care 
4. National Institutes of Health Stroke Scale (NIHSS) score ≥ 5 at time of randomization  
5. Signed informed consent by subject or authorized representative 
6. Agreement to use effective birth control throughout the study (i.e., Day 90): 
a. Males - barrier method of contraception plus a spermicide  
b. Females of childbearing potential (i.e., not surgically sterile or post-menopausal 
defined as age > 51 years without menses for ≥ 2 years) – hormonal 
contraception or barrier method of contraception plus a spermicide  
7. Willing (subject and/or caretaker) to commit to follow-up assessments  
8. Mechanical thrombectomy subjects only: onset (last-seen-well) time to arterial puncture 
time < 6 hours 
Exclusion Criteria: 
Neurological 
1. Rapid spontaneous improvement of neurological signs during screening  
2. History of stroke or penetrating head injury within 90 days prior to enrollment 
3. History of previous or current diagnosis of intracranial hemorrhage (i.e., intracerebral, 
epidural, subdural or subarachnoid) that represents—in the opinion of the investigator—a 
potential for re-hemorrhage if subjected to thrombolytic therapy or mechanical 
thrombectomy.  
4. Moyamoya disease, cerebral arterio-venous malformation (AVM), or known unsecured 
aneurysm requiring intervention during the acute study period (Days 1 to 30) 
5. Presence of other neurological or non-neurological co-morbidities (e.g., intracerebral 
neoplasm, metabolic encephalopathies, hemiplegic migraine, multiple sclerosis, 
convulsive disorder, monocular blindness) that, in the Investigator’s opinion, may lead, 
independently of the current stroke, to further deterioration in the subject’s neurological 
status during the trial period, or may render the study’s neurological assessments 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 17 of 81 
inconclusive for the purpose of evaluating the effect of investigational product on the 
stroke 
6. Presence of premorbid neurological deficits and functional limitations assessed by a 
retrospective Modified Rankin Scale (mRS) score of ≥ 2 
7. Mechanical thrombectomy subjects only: baseline non-contrast computed tomography 
(CT) scan revealing a large core occlusion as defined by local protocol, for example an 
ASPECTS below a locally defined value or baseline CT perfusion data 
Non-Neurological  
8. Prolonged prothrombin time (INR >1.7) 
9. Prolonged partial thromboplastin time (PTT) that exceeds the upper limit of normal (ULN) 
10. Use of heparin within the 48 hours prior to enrollment, except to maintain catheter 
patency 
11. Severe hypertension (systolic blood pressure [BP] > 185 mm Hg or diastolic BP > 110 
mm Hg) or hypotension (systolic BP < 90 mm Hg), as measured by at least 2 consecutive 
supine measurements 10 minutes apart, that does not respond to simple treatment (e.g., 
1 dose of labetalol or nicardipine infusion) 
12. Estimated glomerular filtration rate (GFR) <35 mL/min 
13. Blood glucose concentration < 50 mg/dL  
14. Prior exposure to any exogenous form of APC (e.g., plasma-derived APC, 3K3A-APC, 
Xigris,® drotrecogin alfa [activated])  
General 
15. Weight > 129 kg 
16. Unable to undergo MRI per local guidelines  
17. Pregnancy or breastfeeding 
18. Current abuse of alcohol or illicit drugs 
19. Received treatment with an investigational drug or device within 30 days prior to 
enrollment 
20.  Any other condition that, in the opinion of the Investigator, may adversely affect the 
safety of the subject, the subject’s ability to complete the study, or the outcome of the 
study 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 18 of 81 
1 
STUDY OBJECTIVES 
1.1 
Primary Objectives 
• 
To evaluate the safety of multiple ascending intravenous (IV) doses of 3K3A-APC following 
tPA administration or mechanical thrombectomy or both in subjects who have experienced 
moderate to severe acute ischemic stroke. 
1.2 
Secondary Objectives 
• 
To investigate the PK properties of 3K3A-APC following tPA or mechanical thrombectomy 
or both in adults with acute ischemic stroke. 
• 
To evaluate the effect of 3K3A-APC on the presence of tPA/mechanical thrombectomy-
related bleeding in the brain (hemorrhage and microbleeds) as determined by MRI at Day 
30. 
1.3 
Exploratory Objectives 
• 
To evaluate the effect of 3K3A-APC on the volume of tPA/mechanical thrombectomy-
related bleeding (hemorrhage and microbleeds) in the brain as determined by MRI at Day 
30. 
• 
To evaluate the effect of 3K3A-APC on incidence of subarachnoid hemorrhage in subjects 
who receive mechanical thrombectomy. 
• 
To collect the 7-day National Institutes of Health Stroke Scale (NIHSS) scores as a 
predictor for 90-day modified Rankin Scale (mRS). 
• 
To collect the 90-day mRS 
• 
To collect the 90-day Barthel Index (BI) 
• 
To collect infarct volume at 90 days (MRI, or CT if unable to obtain MRI) 
• 
To assess the immunogenic potential of 3K3A-APC 
2 
BACKGROUND  
2.1 
Ischemic Stroke 
A stroke occurs when the blood supply to part of the brain is interrupted (ischemic stroke) or when 
a blood vessel in the brain bursts (hemorrhagic stroke), allowing blood into the spaces surrounding 
brain cells.  Each year about 795,000 people in the United States (US) experience a new or 
recurrent stroke9.  Of all strokes, 87% are ischemic and the remainder are hemorrhagic (75% 
intracerebral hemorrhage and 25% subarachnoid hemorrhage)10.  Ischemic stroke is the third 
leading cause of death and the most common cause of disability in industrialized nations11.   
In ischemic strokes, an artery in the brain is occluded in one of 2 principal ways: thrombotic or 
embolic12.  A thrombotic stroke occurs when diseased or damaged cerebral arteries become 
blocked by the formation of a blood clot within the blood vessels supplying the brain.  An embolic 
stroke is caused by a clot (or emboli) formed somewhere other than in the brain itself.  Often 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 19 of 81 
originating in the heart, these emboli will travel the bloodstream until they become lodged and 
restrict the flow of blood to the brain.  
2.2 
Current Treatment for Stroke 
Currently, the most commonly used approved treatment for acute stroke is thrombolytic therapy 
with recombinant tissue plasminogen activator (rtPA or tPA). tPA is approved for IV administration 
within 3 hours of onset of acute ischemic stroke in the US and for up to 4.5 hours following the 
stroke in Europe2,13.  Thrombolytic therapy with IV tPA up to 4.5 hours following stroke is 
recommended by the American Heart Association/American Stroke Association14. The primary 
adverse effect of tPA in clinical use is symptomatic intracranial hemorrhage (~ 6%); other risks 
include systemic bleeding, myocardial rupture (when used to treat acute myocardial infarction), 
and, in rare cases, anaphylaxis or angioedema13.  Although tPA is widely available in the US, it is 
estimated that only 10 to 20% of stroke patients receive treatment with tPA15,16, principally because 
they present for care  > 3 hours after the onset of symptoms or are at increased risk for bleeding 
from concomitant medication use, or for other reasons. 
Another effective treatment for stroke, albeit less frequently used, is mechanical thrombectomy in 
patients with documented large vessel occlusion4-7. As shown in Table 1, four large, well-controlled 
randomized clinical trials showed benefit of thrombectomy when added to IV tPA treatment. Large 
vessel occlusion is defined as thromboembolic blockage of the distal internal carotid artery (ICA), 
the M1 or proximal M2 portions of the middle cerebral artery (MCA), or the proximal anterior 
cerebral artery (ACA). In some of these trials, however, patients benefited who were ineligible for 
IV tPA and were treated with thrombectomy alone. In 3 prior trials, thrombectomy performed late 
(> 6 hours after stroke onset) did not appear to be successful17-19. These trials also used first 
generation devices whereas the 4 recent trials used second or third generation devices, so the prior 
negative results and more recent positive results could reflect improvements made in the 
thrombectomy technology. Regardless of the mechanism, it is clear that patients benefit when 
treated with latest generation devices very soon (< 6 hours) after stroke onset. Use of mechanical 
thrombectomy, with or without IV tPA treatment, is considered standard of care in patients with 
documented large vessel occlusion. 
 
 
 
 
 
Table 1:  
Summary of Mechanical Thrombectomy Study Outcomes  
KEY – Mechanical Thrombectomy Arm [tPA-only Control Arm] 
 
Trial 
% Achieving 
Reperfusion 
mRS 0-2 
SICH 
Mortality 
ESCAPE4 
72.4%§ [31.2%]¶ 
53% [29.3%] 
3.6% [2.7%] 
10.4% [19.0%] 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 20 of 81 
N=238   
 
p < 0.001 
p = 0.75 
p = 0.04 
EXTEND-I5 
N=70 
89%♯ [34%]♯ 
p < 0.001 
71% [40%] 
p = 0.01 
0% [6%] 
9% [20%] 
MR CLEAN6 
N=500 
58.7%§ 
[57.5]¶ 
32.6% [19.1%] 
(95% CI, 5.9 - 
21.2) 
7.7% [6.4%] 
21% [22%] 
REVASCAT20 
N=206 
65.7%§ [Not 
Reported] 
43.7% [28.2%*] 
(95% CI, 1.1 – 4.0) 
1.9% [1.9%*] 
p = 1.0 
18.4%[15.5%*] 
p = 0.60 
SWIFT PRIME7 
N=196 
82.8%§§ [40.4%]§§ 
p < 0.0001 
60.2% [35.5%] 
p = 0.0008 
1.0% [3.1%] 
p = 0.37 
9.2% [12.4%] 
p = 0.50 
§ Defined as achieving TICI score of 2b or 3  
¶ Defined as achieving mAOL score of 2 or 3  
♯ Defined as reperfusion >90% without SICH  
§§ Defined as reperfusion ≥90% 
*Note: 23 of 103 control pts did NOT rec IV-tPA 
 
2.3 
Study Drug: 3K3A-APC 
3K3A-APC is a 405-residue protein expressed via recombinant technology in Chinese hamster 
ovary (CHO) cells.  Its amino acid sequence differs from that of the wild-type human Activated 
Protein C (APC) and of the product drotrecogin alfa (activated) (Xigris®) in that 3 sequential lysine 
residues have been replaced with 3 sequential amino-acid substitutions (all lysine to alanine); the 
amino acid substitutions are K191A-K192A-K193A.  This change retains the cytoprotective effects 
of native (wild-type) APC while significantly reducing its anticoagulant effects.  Glycosylation of 
3K3A-APC product differs from wild-type APC since it is expressed in CHO cells. 
An important goal in the development of therapeutics intended for the treatment of acute stroke is 
to minimize bleeding risk while maximizing efficacy. 3K3A-APC is an APC variant that has been 
genetically engineered to maximize neuro- and cytoprotective activity and minimize anticoagulant 
activity.  3K3A-APC was developed by altering factor Va binding exosites (reducing 
anticoagulation) in APC without affecting exosites that recognize PAR1.  
In in vitro assays, 3K3A-APC retains the cytoprotective activity of recombinant wild-type (rwt) APC 
but has < 10% of its anticoagulant activity (e.g. see Table 2 below21). 
 
Table 2:  
Cytoprotective and Anticoagulant Activity of rwt-APC versus 3K3A-APC 
APC Type 
Anticoagulant 
Activity (% rwt)1 
Cytoprotective 
Activity (% rwt)2 
Cytoprotective to 
Anticoagulant Ratio 
rwt-APC   
100 
100 
1.0 
3K3A-APC 
4.6 
114 
25 
1Based on the activated partial thromboplastin time (aPTT) dose-response  

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 21 of 81 
2Derived from the concentrations of APC required for half-maximal inhibition of apoptosis induced 
by the protein kinase inhibitor, staurosporine 
 
2.3.1 
Rationale for APC in Treating Stroke 
APC is an endogenous serine protease with systemic anticoagulant, anti-inflammatory, and anti-
apoptotic activities22.  APC’s anticoagulant activity is independent of its cellular effects. Its 
anticoagulant activity is mediated by irreversible proteolytic degradation of factors Va and VIIIa with 
contributions by various cofactors, whereas its cytoprotective activities are mediated by proteolytic 
activation of protease activated receptor 1 (PAR1)23.  Both properties (anticoagulant and 
cytoprotective) may be useful in reversing the effects of an ischemic stroke (via thrombolysis) and 
in protecting the ischemic brain tissue from further damage.  APC’s cellular signaling results in 
cytoprotective alterations in gene expression profiles resulting in anti-inflammatory activity and anti-
apoptotic activity24-28. APC is generated from zymogen protein C that is activated by thrombin on 
the surface of endothelial cells. The activation requires 2 membrane receptors, thrombomodulin 
and endothelial protein C receptor (EPCR) (Figure 2). 
 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 22 of 81 
Figure 2:   
Blood Coagulation and Protein C Pathway 
 
As noted above, APC acts directly on vascular and neuronal cells to exert multiple cytoprotective 
effects, mediated by its interaction with EPCR and the effector receptor, PAR-123. Specifically, APC 
protects neurons and brain endothelial cells from ischemic injury and cell death caused by a variety 
of apoptotic pathways24,29-31. Early post-ischemic administration of APC within 4 hours of an 
ischemic insult is neuroprotective in rodent models of transient ischemia24,32 and embolic stroke33. 
Delayed APC administration beginning at 6 hours following ischemic insult with continued bolus 
dosing 24, 48 and 72 hours following insult, is neuroprotective and mediates brain repair (i.e., 
neovascularization and neurogenesis), suggesting a significant extension of the therapeutic 
window for APC intervention in postischemic brain34. 
2.3.2 
Rationale for use of APC following tPA or Mechanical Thrombectomy  
The most frequently used FDA approved treatment for stroke is thrombolysis with recombinant 
human tPA13. Certain mechanical devices have received FDA approval for clot retrieval, and as 
shown above, mechanical thrombectomy has been shown to be effective in certain patients as a 
stroke therapy. All patients who meet tPA or mechanical thrombectomy treatment criteria and who 
arrive to the hospital acutely will receive tPA (within 4.5 hours of onset) or mechanical 
thrombectomy (within 6 hours of onset) or both, as standard of care. Neuroprotection appears to 
work best if delivered within 6 hours and in the setting of recanalization/reperfusion35. Thus, the 
best way to study putative neuroprotectants is to combine them with recanalization treatments, 
which, if successful, results in reperfusion of ischemic tissue.  
The combination of tPA and 3K3A-APC raises potential safety concerns. However, in all likelihood, 
there will be no tPA circulating by the time the first dose of 3K3A-APC begins. Modeled PK data for 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 23 of 81 
tPA administration in stroke are shown in Section 5.5.1. The terminal half-life of tPA is ~5 minutes 
and these modeled data predict that circulating levels of tPA are nearing 0 µg/mL by 30 minutes 
following completion of the infusion. In this study, 3K3A-APC or placebo will be given 30-120 
minutes following administration of tPA, and therefore little to no circulating tPA is expected to be 
present during infusion of the IMP. 
Studies of wt-APC—which has greater anti-coagulant potential than 3K3A-APC—in combination 
with tPA provide safety reassurance. Despite having anticoagulant properties, wt-APC has been 
shown to reduce tPA-induced bleeding and neurotoxicity in preclinical models, probably due to the 
anti-inflammatory and anti-apoptotic activity previously discussed24,29,31,32,36. There is, however, a 
theoretical concern that administration of 3K3A-APC following tPA could have deleterious effects 
on coagulation or clot lysis. The effects of tPA on the anticoagulant activity of 3K3A-APC have been 
studied using aPTT clotting assays in vitro; tPA at a concentration of 3 µg/mL had little to no effect 
on the anticoagulant activity of either wt-APC or 3K3A-APC (Figure 3). Since we expect tPA levels 
to be virtually undetectable at the time of 3K3A-APC administration, we expect there will be no 
additional prolongation of aPTT in this study. 
Figure 3:   
The effects of tPA on the anticoagulant activity of 3K3A-APC and wt-APC in 
aPTT assays 
 
Figure Key: (A) Prolongation of the aPTT assay beyond the baseline reference clotting time of 47 
sec was determined for plasma-derived wt-APC (open symbols) and for 3K3A-APC (solid symbols) 
when tPA was present at 0 (circles, solid lines) or 3.0 µg/mL (squares, dashed lines). Data show 
difference between observed aPTT value and control value of 47 sec.  (B) The influence of tPA on 
the anticoagulant activity of 3K3A-APC was determined at the indicated concentrations (0, 45, 90, 
140 nM). The tPA concentrations (µg/mL) were as follows:  0 (black bar), 0.5 (
), 1.0 (red bar), 3.0 
(blue bar). Data show obseved aPTT values. 
 
10
100
10
100
4
8
60
20
40
6
160
20
30
50
70
A
wt-APC
3K3A-APC
3 g/ml tPA
0 g/ml tPA
APC (nM)
APTT Prolongation (sec)
0
50
100
150
0
45
90
140
B
0 tPA
0.5 tPA
1 tPA
3 tPA
g/ml
3K3A-APC (nM)
APTT (sec)

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 24 of 81 
The effects of 3K3A-APC on the fibrinolytic activity of tPA has also been studied in vitro; no 
statistically significant effects on the ability of tPA to induce clot lysis were observed by either wt-
APC or 3K3A-APC37. Thus, we expect no impact on clot lysis in this study, either.   
In summary, ischemic stroke patients who are eligible to receive tPA or mechanical thrombectomy 
or both are the most likely patient population to benefit from a neuroprotectant like 3K3A-APC, due 
to the need for reperfusion.  Circulating tPA is cleared quickly from the body and levels are expected 
to be nearly undetectable by the time 3K3A-APC will be administered.  Even so, in vitro studies 
show that there is minimal effect on 3K3A-APC coagulation and no significant effect on tPA clot 
lysis when both drugs are present at clinically relevant doses. 
2.3.3 
Recombinant Human APC (drotrecogin alfa [activated], Xigris®) 
Xigris® [drotrecogin alfa (activated)] (Eli Lilly and Company, Indianapolis, IN) is a recombinant wild-
type APC having the same amino acid sequence as the naturally occurring APC.  Xigris® was 
approved in the US in 2001 (and in the EU in 2002) for treatment of severe sepsis.  Although Xigris 
is no longer marketed because of lack of efficacy in a large post-marketing trial in patients with 
severe sepsis, bleeding was a dose-limiting side effect38.   
In the 1690-subject placebo-controlled study that was the basis for approval, the Xigris® arm had a 
higher proportion of patients with treatment-emergent adverse events of bleeding than did the 
placebo arm at all levels of severity, i.e., mild: 10.5% versus 7.7%; moderate: 5.5% versus 1.8%; 
and severe: 2.8% versus 1.3%. Serious bleeding events (e.g., gastrointestinal, intrathoracic or 
intracranial) were associated with Xigris® (3.5% versus 2.0% in placebo, p = 0.06), occurring more 
commonly in patients with predisposing conditions for bleeding, such as gastrointestinal ulceration, 
traumatic injury of a blood vessel or vascular organ, low platelet count or markedly abnormal 
parameters of coagulation (PT or aPTT)39.  The FDA-approved labeling for Xigris® (2008) reported 
an approximately 1% risk of intracerebral hemorrhage in sepsis patients during continuous 
infusion.  There were no statistically significant differences between the two treatment groups in 
the percentage of patients who experienced at least one serious adverse event during the study 
drug infusion period (6.8% of Xigris-treated patients versus 6.5% of placebo-treated patients) or 
during the 28-day study period (12.5% of Xigris-treated patients versus 12.1% of placebo-treated 
patients). 
Xigris® was recently under study in a Phase 1/2, multi-center, dose escalation safety and feasibility 
trial for treatment of acute ischemic stroke [Activated Protein C in Acute Stroke Trial (APCAST)]40, 
however the study was terminated prematurely due to insufficient recruitment.  As of September 
2013, study results were not publically available. 
2.4 
Nonclinical Studies of 3K3A-APC 
2.4.1 
Efficacy in Animal Models of Stroke 
3K3A-APC has been tested for neuroprotective activity in several mouse models of stroke. In a 
murine model of embolic stroke, an intact clot was placed at the origin of the middle cerebral artery, 
and functional neurological testing and histopathological analyses were conducted for 7 days 
following the stroke41.  In this study, a single IV dose of 2.0 mg/kg of 3K3A-APC, administered 4 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 25 of 81 
hours after stroke as a 50% bolus followed by 50% infusion over 30 minutes, significantly improved 
functional recovery and neurological scores, and reduced infarct and edema volume in the brain.  
In murine models of middle cerebral artery occlusion (MCAO), the artery was occluded for 1 hour 
followed by 24 hours of reperfusion (transient MCAO model) or was permanently ligated 
(permanent MCAO model). Animals were assessed for neurological function, neuropathology, and 
hemoglobin content in the ischemic areas of the brain for up to 7 days after stroke.  3K3A-APC 
significantly improved neurological function and histopathology scores relative to vehicle control 
animals at single doses of 0.4 or 2.0 mg/kg, administered 5 minutes prior to transient MCAO, and 
at multiple doses of 1 mg/kg administered 12 hours and 1, 3, 5, and 7 days following permanent 
MCAO42. The improvement in neurological function and histopathology scores following 3K3A-APC 
monotherapy was superior to that observed with comparable doses of recombinant wild type APC 
(rwt-APC). In addition, in both MCAO models, rwt-APC treated animals showed increased 
hemoglobin content in the brain, indicative of bleeding, compared to vehicle controls or 3K3A-APC-
treated mice.  
3K3A-APC acts synergistically with tissue plasminogen activator (tPA) in both mouse and rat stroke 
models43. Human recombinant tPA (10 mg/kg), alone or in combination with human recombinant 
3K3A-APC (2 mg/kg), was administered intravenously 4 hours after proximal or distal transient 
MCAO in mice or embolic stroke in rats, followed by 3K3A-APC for 3 to 4 consecutive days after 
stroke. In this delayed treatment paradigm, tPA alone had no beneficial effects on infarct volume 
or behavior (neurological score, foot-fault, forelimb asymmetry, adhesive removal) compared with 
vehicle. In contrast to either therapy alone, the tPA plus 3K3A-APC combination significantly 
reduced infarct volume at 24 hours and at 7 days following proximal or distal transient MCAO in 
mice and at 7 days after embolic stroke in rats, by 65%, 63%, and 52%, respectively, (P<0.05; 
determined by one-way analysis of variance followed by Tukey post hoc test) compared to vehicle 
control. Further, the combination significantly improved behavioral outcomes and eliminated tPA-
related intracerebral microhemorrhages (p< 0.01 to 0.05).  
These positive effects of 3K3A-APC extend to elderly animals and animals with comorbidities such 
as might be seen in the target patient population of this study. Murine recombinant 3K3A-APC (0.2 
mg/kg) alone or with recombinant tPA (10 mg/kg) was given intravenously 4 hours after transient 
MCAO in aged female mice and 4 hours after embolic stroke in spontaneously hypertensive rats44. 
3K3A-APC was additionally administered within 3 to 7 days after stroke. Neuropathological analysis 
and neurological scores, foot-fault, forelimb asymmetry, and adhesive removal tests were 
performed within 7 and 28 days of stroke. In all models, tPA alone given 4 hours after stroke had 
no effects on the infarct volume or behavior. 3K3A-APC alone or with tPA reduced the infarct 
volume 7 days after the MCAO in aged female mice and embolic stroke in spontaneously 
hypertensive rat by 62% to 66% and 50% to 53%, respectively, significantly improved (p<0.05) 
behavior, and eliminated tPA-induced intracerebral microhemorrhages. 
In summary, 3K3A-APC appears to have less anticoagulant effect and provides greater 
neuroprotection than rwt-APC in mouse models of stroke; when 3K3A-APC is combined with tPA, 
infarct volumes are reduced and intracerebral microhemorrhages are zero.  At the same time, 
behavioral outcomes in both mouse and rat models of stroke are improved. 3K3A-APC also 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 26 of 81 
extends the therapeutic window of tPA in ischemic stroke models in rodents, supporting further 
development of tPA and 3K3A-APC combination therapy for focal ischemic stroke in humans. 
2.4.2 
Toxicology Studies 
Two 14-day Good Laboratory Practice (GLP) toxicology studies were performed in mice and 
monkeys. Doses of 0.4, 2.0, or 5.0 mg/kg were administered by IV bolus once daily to mice, and 
doses of 0.2, 1.0, or 5.0 mg/kg were administered by IV bolus once daily to monkeys.  Endpoints 
included clinical signs, body weights, food intake, clinical chemistry and hematology, coagulation 
parameters, and histopathology. 3K3A-APC plasma concentrations were measured on Days 1 and 
14 for toxicokinetic assessment.  Sera were also obtained to evaluate the potential of 3K3A-APC 
to induce antibodies in both species.  
No clinical signs of toxicity, no effects on hematology or clinical chemistry parameters, and no 
histopathological changes indicating target organ toxicity were observed.  No drug-related effects 
on neurological, respiratory, or cardiovascular functions were observed in monkeys.  However, 
dose-related increases in aPTT were observed on Days 1 and 14, with increases of approximately 
1.5- and 4.5-fold control values at doses of 1 and 5 mg/kg of 3K3A-APC, respectively. PT was 
increased approximately 1.4-fold of control values at the highest dose (5.0 mg/kg) only. The 
elevated aPTT and PT values were lower 3 hours after injection and values returned to normal 24 
hours post injection.  The changes in coagulation parameters were not associated with clinical 
signs of bruising or bleeding in monkeys. 
The no observed adverse effect level (NOAEL) of 3K3A-APC in the mouse and monkey toxicology 
studies was 5.0 and 0.2 mg/kg/day, respectively, which represent human equivalent doses (HEDs) 
of 0.40 and 0.06 mg/kg (400 and 60 µg/kg), respectively. 
In a separate study, rwt-APC was administered IV in ascending doses to cynomolgus monkeys and 
PT and aPTT were measured 15 min, 3 hr and 24 hr after dosing.  The magnitude of the 
anticoagulant effect (~ 1.4-fold increase from baseline) at 0.1 mg/kg was similar to the effect of 
3K3A-APC at 1.0 mg/kg.   
Antibodies to 3K3A-APC were detected in mice and monkeys treated with multiple doses of 3K3A-
APC. No apparent relationship to dose was observed in either species. The generation of 
antibodies in these species is expected since 3K3A-APC is a protein of human origin.  
 
2.5 
Clinical Studies of 3K3A-APC 
A Phase 1 study, ZZ-3K3A-001, was conducted in 64 healthy adult volunteers to characterize the 
safety and PK profile of single ascending and multiple ascending IV doses of 3K3A-APC. 
Intravenous administration of 3K3A-APC or matching placebo to cohorts of healthy adult volunteers 
at doses up to 720 μg/kg single-dose and 540 μg/kg multiple-dose (every 12 hours for 5 doses) did 
not result in any serious adverse events, severe adverse events or withdrawal from study due to 
an adverse event. After review of AEs (moderate headache, nausea and vomiting and mild vertigo) 
in 1 of the 2 subjects who received a single-dose of 720 µg/kg of 3K3A-APC, the SRC 
recommended reducing the dose to 540 µg/kg in subsequent subjects in the cohort. For that 
reason, 540 μg/kg was the highest dose evaluated in the multiple-dose cohorts. In summary, the 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 27 of 81 
evaluated safety measures indicate that 540 µg/kg is tolerated in single and multiple dosing in 
healthy volunteers. 
 
The most common adverse events reported were mild or moderate; headache, hypertension, 
nausea and vomiting were reported in 54%, 8%, 8% and 4% of the 3K3A-APC treated subjects 
(n=50) respectively. Rates for the same events in placebo subjects (n=14) were 7%, 21%, 7% and 
0%, respectively.  
 
The majority of the drug-related AEs were headache; of subjects who received active drug across 
the four highest doses, headache occurred at least once in 3/10 (30%) subjects receiving 180 
µg/kg, in 8/10 (80%) subjects receiving 360 µg/kg, in 9/10 (90%) subjects receiving 540 µg/kg and 
in 2/2 (100%) subjects receiving 720 µg/kg. Headache was reported in 1/14 (7%) subjects who 
received placebo. These data indicate that headache is related to 3K3A-APC exposure and 
appears to increase in frequency with dose. In no patient did headache lead to interruption of IMP 
or require treatment other than acetaminophen pain reliever.  
 
Hypertension was reported with the second highest frequency; ten AEs of hypertension assessed 
as being related to the treatment occurred during the study. Four (4) of these AEs occurred in 
placebo-treated subjects (21% of all placebo-treated subjects), and 6 of these AEs occurred in 
3K3A-APC-treated subjects (8% of all actively treated subjects). No association of hypertension 
with 3K3A-APC could be ascribed. 
 
Increases in the coagulation parameters, aPTT and to a much lesser extent, PT, were observed 
following administration of 3K3A-APC; however, the magnitudes of the changes were not 
considered clinically significant. Elevations above the normal range for aPTT and PT were seen in 
30% and 6% of 3K3A-APC-treated subjects (doses ranging 180 – 720 µg/kg only), respectively, 
and in 21% and 0% of placebo subjects, respectively. The highest aPTT level observed in a single 
subject was 1.51 times ULN (60.4 sec) at 1 hour following infusion #4 of 360 µg/kg. The highest 
observed PT in a single subject was 1.02 times ULN (16.1 sec) at 1 hour following infusion #2 of 
540 µg/kg. The majority of elevated values returned to within normal limits by 2 hours following 
each dose.  No clinical signs of bleeding or bruising were observed in the study subjects despite 
the mild prolongations in coagulation parameters.   
 
Repeated evaluation of blood chemistry, hematology and coagulation yielded no AEs related to 
placebo or active treatment. Vital signs other than blood pressure (heart rate, body temperature 
and respiratory rate) also did not yield any abnormalities in both treatment groups. There were no 
clinically significant ECG or QTc changes noted in 3K3A-APC-treated subjects.  
 
No subject tested positive for anti-3K3A-APC antibody formation following administration of 3K3A-
APC. 
 
Dose-related systemic exposure to 3K3A-APC (measured by a validated enzyme-immunocapture 
assay of 3K3A-APC amidolytic activity in plasma) was observed at dose levels of 30 μg/kg and 
greater. No evidence of accumulation of 3K3A-APC was observed in the multiple-dose cohorts.  

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 28 of 81 
Based on compartmental modeling, mean Cmax ranged from 249 to 5,715 ng/mL (30 and 720 µg/kg, 
respectively); mean values for CL (11,693 to 18,701 mL/h) and V (4,873 to 6,971 mL) were 
independent of dose as was the t½ with a mean of approximately 0.25 h (range 13 to 18 min). 
 
In summary, 540 µg/kg was tolerated in single- and multiple-dosing. The most common effects of 
3K3A-APC observed in the single clinical study conducted were mild dose-related reversible 
increases in coagulation parameters (aPTT and PT) and mild and moderate dose-related, transient 
adverse events of headache, hypertension, nausea and vomiting. 
2.6 
Rationale for Dose Selection 
3K3A-APC is delivered via intravenous infusion over 15 minutes.  Brief intravenous infusions were 
selected for subjects because in all studies in rodents 3K3A-APC was administered using brief 
single systemic infusion41,42,45-47. Short term dosing is preferred over longer infusions of drug 
because APC neuroprotection occurs predominantly via cytoprotective cell signaling mechanisms.  
Repeated administration of high dose 3K3A-APC has been remarkably successful in preclinical 
models, likely because this homeostatic enzyme (half-life circa 16 min) acts directly on cells to alter 
gene-expression profiles and to stabilize endothelial barrier function. 3K3A-APC engages 
therapeutically relevant signaling pathways that reduce inflammation, vascular leakage, and 
apoptosis36. Low-dose, long-term infusions of this enzyme are less likely to reboot multiple cell 
protective mechanisms because initiation of cell signaling benefits from higher doses of agonist. 
Therefore, short term bolus dosing should achieve maximum benefits for changing the status of 
cell signaling networks.  Furthermore, bolus dosing will eliminate the risk of zymogen factor V and 
VIII consumption that is associated with the continuous infusion of rwt-APC. 
The proposed doses of 3K3A-APC for evaluation in the study are 120, 240, 360 and 540 µg/kg.  
These doses are based on the doses and administration that were tested in the Phase 1 clinical 
study in normal human volunteers during which single- and multiple-dose (q12 hours for 5 doses) 
infusions were well tolerated at doses up to 540 μg/kg. The proposed doses also cover a range 
that is expected to achieve circulating levels of 3K3A-APC that correlate with preclinical efficacy, 
or about 2000 ng/mL. In mouse studies, the dose of murine 3K3A-APC that exerts maximal 
protective effect in mice is 200 μg/kg41, which is similar to murine wt-APC24. A clinical dose of 240 
µg/kg of 3K3A-APC is expected to achieve similar circulating levels.  
3 
STUDY DESIGN 
3.1 
Study Design and Enrollment: 
This is a multicenter, prospective, randomized, controlled, double-blinded Phase 2 study intended 
to evaluate the safety, PK and preliminary efficacy of 3K3A-APC following administration of tPA or 
mechanical thrombectomy or both in subjects with moderate to severe acute ischemic stroke.  
Approximately 115 subjects will be enrolled, which includes the planned 88 subjects in groups of 
four to either 3K3A-APC or placebo (in a 3:1 ratio) and the additional placebo subjects who will be 
enrolled during safety review pauses. This study will utilize a modified version of the CRM in order 
to establish a MTD. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 29 of 81 
Following completion of tPA infusion or initiation of mechanical thrombectomy (arterial puncture), 
whichever is sooner, eligible adult subjects will receive study treatment 30 to 120 minutes later 
given as a 15-minute infusion. Subjects will receive another 15-minute infusion of 3K3A-APC every 
12 hours (+/- 1 hour) for up to 5 total doses.  The initial cohort dose of 3K3A-APC will be 120 μg/kg; 
the other dose levels that will be evaluated with the CRM are 240, 360, and 540 μg/kg. After the 
final group of subjects is enrolled, the final MTD will be defined as the highest dose with estimated 
toxicity probability less than or equal to the target toxicity level of 10%. 
Enrollment will proceed as follows: 
• 
Enroll the first 4 subjects in cohort 1. 
o 
Treat one of the four subjects (chosen randomly) with placebo. 
o 
Treat the other three subjects with the lowest dose: 120 µg/kg. 
o 
Observe the number of subjects (out of the three treated subjects) that have a DLT per 
study definition. Any given subject who receives only one dose of study drug and does 
not experience a DLT will not be included in the CRM calculation (i.e. two or more 
doses will need to be administered to be included). 
o 
Based upon the observed information from the three treated subjects, refit the 
assumed dose-response curve. 
• 
Initially (through version 7.1. of the protocol), the re-estimated dose-response curve using all 
cohorts enrolled to date was then used to determine the highest dose level of the four under 
consideration that has an estimated probability of toxicity less than or equal to 10% 
o 
The next cohort of subjects is treated at the dose level specified above – unless the 
chosen dose level is more than one level higher than the current level.  If so, treat the 
next cohort of subjects at the next dose level above the current level. 
• 
Based on a DSMB recommendation, this process was changed as of version 8.0 of the 
protocol.  The basic process proceeds as described above, but once all subjects in a given 
cohort (n) have been enrolled, data from all prior cohorts (cohort 1, cohort 2, ….., cohort n-1) 
are used to determine the dose level of cohort n+1. 
o 
If enrollment is rapid such that both cohort (n-1) and cohort (n) are filled and awaiting 
DLT review, new subjects enrolled will be randomized to placebo until cohort (n-1) 
has been reviewed. (For example, if both cohort 13 and 14 are filled and awaiting 
review, subjects will be randomized to placebo until cohort 13 is closed and the 
model is rerun to determine the dose for cohort 15.) 
The MTD will be defined as the dose that would be chosen from the CRM at the final step.  The 
study will stop once the first of the following criteria have been met: 
• 
The maximum number of cohorts (22) has been observed. 
• 
If at any time after half of the cohorts (11) have been observed, two consecutive iterations 
suggest a 15% or higher toxicity rate at the lowest dose (stop for safety) 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 30 of 81 
• 
If the study proceeds straight to the highest dose, and then observes 9 successive cohorts at 
the highest dose with no observed toxicity (stop and declare highest dose the MTD) 
Through simulation it was determined that it would be extremely unlikely to observe no DLTs after 
9 successive cohorts if the true toxicity rate were 10%. Thus, after 9 cohorts we would have 
sufficiently determined that all doses under consideration are safe and stopping early would be 
justified. 
Non-serious adverse events (AEs) will be collected through actual Day 7, and SAEs collected 
through actual Day 30. More specifically, subjects will be evaluated for DLTs from administration 
of the first dose to 48 hours following the last dose of study treatment. Blood samples for PK will 
be collected from approximately 40 subjects at a sub-set of study sites following one of the 5 doses 
of 3K3A-APC at the following time points: end of infusion and 20, 40, 60 and 80 minutes after the 
end of infusion. Subjects must be seen for assessments on Days 7, 14, 30 and 90. MRI scans, 
including SWI sequences, will be obtained at 7 (or discharge) and 30 days after stroke. 
3.1.1 
Dose Limiting Toxicities: 
Toxicities that require grading will use the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE), Version 4.03.   
Dose-limiting toxicities will be assessed from the first dose to 48 hours following the last dose of 
study treatment (unless specified below) and defined as any of the following AEs that have an 
attribution of “related” to study treatment (possibly, probably, and definitely): 
• 
An aPTT following any dose that reaches 2 x the ULN at 1 hour post-dose. Upper limit 
of normal range is defined locally by the site laboratory. 
• 
SICH defined as blood present on CT or MRI brain images that is associated with clinical 
worsening that meets the definition of neuroworsening (4 or more point increase in 
NIHSS; see section 9.4.1.3 for definition) and in the opinion of the investigator represents 
a clinically significant change that can be attributed to the hemorrhage. Subarachnoid 
hemorrhage that occurs in subjects who receive mechanical thrombectomy will NOT be 
considered a DLT, and instead will be evaluated in an exploratory analysis upon study 
completion.   
• 
Laboratory findings that meet all of the following three components (Hy’s Law): 
▪ 
≥3 x ULN of ALT or AST,  
▪ 
In combination with a serum total bilirubin (TBL) >2 x ULN, without initial 
findings of cholestasis (serum ALP activity >2 x ULN), 
▪ 
And, no other reason can be found to explain the combination of increased 
aminotransferase (AT) enzymes and TBL, such as viral hepatitis A, B, or C, 
preexisting or acute liver disease, or another drug capable of causing the 
observed injury. 
• 
Any other bleeding event classified as serious by the Investigator, or any bleeding that 
required the administration of more than 2 units of packed red cells over any two 
consecutive days. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 31 of 81 
• 
Any Grade 3 laboratory value that, in the opinion of the Investigator, is related to study 
treatment. Refer to CTCAE v4.03 sections relevant to laboratory investigations.  
• 
Any adverse event that, in the opinion of the Investigator, is related to study treatment 
and leads to cessation of further dosing. 
NOTE: All suspected DLTs will be reviewed by a Safety Review Committee, and those reported 
DLTs that are considered possibly related to study drug but definitely related to another event will 
not be considered DLTs upon final adjudication. An example of such an event would be an elevated 
aPTT following dose 1 in a subject who undergoes mechanical thrombectomy during which heparin 
is administered; the elevated aPTT can be attributed to the heparin and therefore should NOT be 
considered a DLT in this isolated instance. Another example would be the occurrence of 
hypofibrinogenemia in a subject who receives tPA. Low fibrinogen levels can be attributed to tPA, 
and there is a documented rate of occurrence of 11% in subjects receiving tPA8. Furthermore, 
3K3A-APC does not cause a reduction in the level of fibrinogen in plasma and therefore this finding 
should NOT be considered a DLT. 
Should a subject experience a DLT, dosing of study treatment should be discontinued as soon as 
the Investigator becomes aware of the event.  
 
3.1.2 
Safety Review Committee: 
An independent Safety Review Committee (SRC) will be formed and charged with reviewing and 
adjudicating DLTs in order to objectively inform the CRM as described in section 8.1.1. The SRC 
will be comprised of a committee chair, the IMM and three qualified participants, as outlined in the 
‘Safety Review Committee Charter.’ Should a DLT be reported or suspected, the DCC will notify 
the SRC, which will be convened to review the AE(s). If a DLT is confirmed by the SRC, the 
NeuroNEXT statistics group will be informed so that the safety event can be fed into the CRM and 
the dose level determined automatically by the model for the next cohort needing a treatment level 
assignment. The SRC will be responsible for final determination of whether a particular event will 
be classified as a DLT, but will not participate directly in dose selection. Refer to ‘Safety Review 
Committee Charter’ for details. 
 
3.1.3 
Data Monitoring and Data Safety Monitoring Board: 
The monitoring of subject safety and data quality will follow the NINDS Guidelines for Data and 
Safety Monitoring in Clinical Trials.  A Data and Safety Monitoring Board (DSMB) appointed by the 
NIH/NINDS will meet at approximately six-month intervals (or as determined by the NINDS) to 
review partially unblinded study data provided by the study statistician.  This committee will monitor 
rates of adverse events and endpoints in the trial and will monitor the performance of the trial. The 
frequency and format of DSMB meetings, reports, and guidelines for interim analysis will be agreed 
upon prior to study subject enrollment.  The PPI will appoint an IMM to review all adverse events, 
in a blinded fashion. The IMM will perform a review of Day 1-7 data (including non-serious AEs) on 
Day 8 to look for missed DLTs. During that same Day 8 review the IMM will evaluate for safety and 
for neuroworsening all AEs that have been reported. Any non-serious AEs that occur during the 
DLT period but are not reported until after the Day 8 review will be evaluated in real time by the 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 32 of 81 
IMM for safety, neuroworsening, and DLTs. Any non-serious AEs that occur after the DLT 
observation period can be reviewed on a quarterly basis or sooner at the discretion of the IMM. In 
addition the IMM will review all events that meet the regulatory definition of a Serious Adverse 
Event (SAE), upon receipt of notification via the Electronic Data Capture (EDC) system, for safety, 
neuroworsening and DLTs. See the Safety Management Plan for more detail.    
4 
SELECTION AND ENROLLMENT OF SUBJECTS 
4.1 
Inclusion Criteria 
1. Age 18 to 90 years, inclusive 
2. Acute ischemic stroke defined as focal, neurological deficit(s), secondary to a presumed 
vascular occlusive event 
3. Able to receive IV tPA per local standard of care, OR, begin mechanical thrombectomy 
per local standard of care. 
4. National Institutes of Health Stroke Scale (NIHSS) score ≥ 5 at time of randomization  
5. Signed informed consent by subject or authorized representative 
6. Agreement to use effective birth control throughout the study (i.e., Day 90): 
a. Males - barrier method of contraception plus a spermicide  
b. Females of childbearing potential (i.e., not surgically sterile or post-menopausal 
defined as age > 51 years without menses for ≥ 2 years) – hormonal 
contraception or barrier method of contraception plus a spermicide  
7. Willing (subject and/or caretaker) to commit to follow-up assessments 
8. Mechanical thrombectomy subjects only: onset (last-seen-well) time to arterial puncture 
time < 6 hours 
4.2 
Exclusion Criteria 
Neurologic 
1. Rapid spontaneous improvement of neurological signs during screening  
2. History of stroke or penetrating head injury within 90 days prior to enrollment 
3. History of previous or current diagnosis of intracranial hemorrhage (i.e., intracerebral, 
epidural, subdural or subarachnoid), that represents—in the opinion of the investigator—
a potential for re-hemorrhage if subjected to thrombolytic therapy or mechanical 
thrombectomy 
4. Moyamoya disease, cerebral arterio-venous malformation (AVM), or known unsecured 
aneurysm requiring intervention during the acute study period (Days 1 to 30)  
5. Presence of other neurological or non-neurological co-morbidities (e.g., intracerebral 
neoplasm, metabolic encephalopathies, hemiplegic migraine, multiple sclerosis, 
convulsive disorder, monocular blindness) that, in the Investigator’s opinion, may lead, 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 33 of 81 
independently of the current stroke, to further deterioration in the subject’s neurological 
status during the trial period, or may render the study’s neurological assessments 
inconclusive for the purpose of evaluating the effect of investigational product on the 
stroke 
6. Presence of premorbid neurological deficits and functional limitations assessed by a 
retrospective Modified Rankin Scale (mRS) score of ≥ 2 
7. Mechanical thrombectomy subjects only: baseline non-contrast CT scan revealing a large 
core occlusion as defined by local protocol, for example an ASPECTS below a locally 
defined value or baseline CT perfusion data 
Non-Neurological 
8. Prolonged prothrombin time (INR >1.7) 
9. Prolonged partial thromboplastin time (PTT) that exceeds the upper limit of normal (ULN) 
10. Use of heparin within the 48 hours prior to enrollment, except to maintain catheter 
patency 
11. Severe hypertension (systolic blood pressure [BP] > 185 mm Hg or diastolic BP > 110 
mm Hg) or hypotension (systolic BP < 90 mm Hg), as measured by at least 2 consecutive 
supine measurements 10 minutes apart, that does not respond to simple treatment (e.g., 
1 dose of labetalol or nicardipine infusion) 
12. Estimated glomerular filtration rate (GFR) <35 mL/min 
13. Blood glucose concentration < 50 mg/dL  
14. Prior exposure to any exogenous form of APC (e.g., plasma-derived APC, 3K3A-APC, 
Xigris,® drotrecogin alfa [activated])  
General 
15. Weight > 129 kg 
16. Unable to undergo MRI per local guidelines 
17. Pregnancy or breastfeeding 
18. Current abuse of alcohol or illicit drugs 
19. Received treatment with an investigational drug or device within 30 days prior to 
enrollment 
20. Any other condition that, in the opinion of the Investigator, may adversely affect the safety 
of the subject, the subject’s ability to complete the study, or the outcome of the study 
4.3 
Subject Discontinuation 
4.3.1 
Subject Withdrawal Criteria 
Subjects may withdraw from the study at any time.  The Site Investigator will document on the 
appropriate case report form (CRF) page the reason/circumstances for withdrawal.   

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 34 of 81 
4.3.2 
Discontinuation of Study Drug 
A subject may be removed from further administration of study drug for the following medical or 
administrative reasons: 
− 
AE/SAE related to study drug, or for another safety reason that, in the opinion of 
the Investigator, is in the best interest of the subject 
− 
Subject was not eligible or becomes ineligible for study, or other major protocol 
deviation that poses a safety risk to the subject 
− 
Subject experiences a DLT 
Efforts will be made to follow all subjects who discontinue study drug for any reason.  Such follow-
up will include all relevant evaluations for safety including clinical assessments and collection of 
laboratory study results as set out in this protocol. 
4.4 
Study Enrollment Procedures 
After beginning tPA or mechanical thrombectomy for moderate to severe acute ischemic stroke, 
subjects or their legally authorized representatives will be presented with the study details and the 
informed consent form (ICF) as described in Section 4.4.3.  
4.4.1 
Subject Recruitment and Retention 
All code stroke patients arriving at the site who receive tPA will be considered for this study. In 
addition, patients ineligible for tPA but considered candidates for mechanical thrombectomy alone, 
and who can begin intra-arterial therapy within 6 hours of symptom onset, will also be considered 
for this study.  The Stroke Team will consider every treated patient for potential enrollment. During 
treatment, the study team will meet with the patient and family to emphasize the critical importance 
of long-term follow up. Every effort should be made by the study team to ensure subjects are seen 
for Day 7 (or discharge), 14, 30 and 90 follow-up visits (e.g., appointment reminder calls, ensuring 
transportation, etc.). Follow-up visits will be coordinated with standard return visits whenever 
possible to minimize patient inconvenience and promote cooperation with follow-up visits. If travel 
distances are significant, the site should contact the CCC for assistance. Study funds are available 
to reimburse patients for ambulance/special needs transportation. The CCC will work with the site 
to determine the reimbursement process and amounts.  Sites may also seek to conduct follow-up 
visits at the subject’s home, nursing home or other facility if the patient cannot travel. The 
NeuroNEXT Recruitment and Retention Committee will work with each site to identify recruitment 
and retention strategies that will be agreed upon and used throughout the study. 
4.4.2 
Reporting of Screening Data 
Screening data documenting the reasons for ineligibility and reasons for nonparticipation of eligible 
subjects will be completed by the study coordinator and submitted to the NeuroNEXT Data 
Coordination Center via the EDC system. All code stroke patients who receive tPA or can begin 
mechanical thrombectomy < 6 hours of last known well time will be considered for this study. Using 
the EDC system, the stroke team study coordinator will record all patients considered for the study, 
and if not eligible, the reason(s) the patient was not enrolled, including specific inclusion or 
exclusion criteria. The coordinator will report as many criteria as applicable per patient. The 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 35 of 81 
screening data will be compiled and provided to the study team and the Protocol Steering 
Committee at an agreed upon frequency.  
4.4.3 
Informed Consent 
Written informed consent will be obtained from each study participant or his/her legally authorized 
representative before any study-specific procedures or assessments are done and after the aims, 
methods, anticipated benefits, and potential hazards are explained. The site PI is ultimately 
responsible for the informed consent process and can delegate the ability to discuss and obtain 
informed consent from study participants to licensed sub-Investigators who are participating in the 
study. All such delegates will sign the “Delegation of Responsibility Log” and agree to adhere to 
the protocol.  The participant’s willingness to participate in the study will be documented in writing 
in a consent form approved by the NeuroNEXT Central Institutional Review Board (CIRB), which 
will be signed by the participant or his/her legally authorized representative with the date of that 
signature indicated. The Investigator will keep the original consent forms and a copy will be given 
to the participant. It will also be explained to the participant that he/she is free to refuse entry into 
the study and free to withdraw from the study at any time without prejudice to future treatment. 
Written and/or oral information about the study in a language understandable by the participant will 
be given to all participants.   
Administration of tPA or initiation of mechanical thrombectomy should not be delayed due to study 
procedures.  The consent process should start after the subject has started treatment with tPA or 
after the decision to begin mechanical thrombectomy has been made, which ever occurs sooner. 
Most pre-study procedures are performed in accordance with standard of care (SOC) for IV tPA 
administration and mechanical thrombectomy and therefore must be performed prior to informed 
consent.  In accordance with good clinical practice, study specific procedures that do not coincide 
with SOC should only be performed after written informed consent is obtained (e.g., collection of 
blood samples for PK or antibody analysis). If, in the opinion of the Site Investigator, the subject’s 
mental status improves sufficiently to enable him/her to provide informed consent, the subject will 
be reconsented in person at the current or next study visit if consent was originally granted by 
another individual. 
 
4.4.4 
Randomization/Treatment Assignment 
Subjects will be randomized using an IWRS to either 3K3A-APC or placebo (in a 3:1 ratio).  Twenty-
two groups of four subjects are planned, but fewer may be enrolled should the study meet either of 
the early stopping criteria (see section 8.1.1). If at any time enrollment is so rapid that there are two 
consecutive cohorts in the DLT review period, subjects will be assigned to placebo until the earlier 
of the two cohorts has been reviewed. The additional placebo subjects will be closely monitored 
and their enrollment may be discontinued should the number enrolled exceed what was planned 
for the study. 
The NeuroNEXT IWR system will also serve to inform the unblinded study pharmacist of the 
treatment assignment (refer to Section 5.3 for details on Study Drug Preparation).  

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 36 of 81 
Randomized subjects who do not go on to receive study treatment for any reason will not be 
included in the study and will be replaced if they were randomized to a cohort. For example, if a 
randomized subject experiences significant neurologic improvement (defined as a NIHSS score 
<5) prior to receipt of study drug he/she will be termed an 'Early Responder' and will not be included 
in the study.  Any subject who receives any amount of study drug or placebo however, will be 
considered "Dosed" and will be followed to the end of the study. 
5 
STUDY DRUG  
5.1 
Description, Packaging, Supply and Labeling 
5.1.1 
3K3A-APC 
3K3A-APC will be supplied by ZZ Biotech using the IWR system.  Adequate drug supply for a single 
subject will automatically be supplied to each investigational site following collection of regulatory 
documents, site training and CIRB approval of the site.  Automatic resupply will occur when the site 
confirms administration of the first dose of drug to a subject in the EDC system; however, the site 
pharmacist will check with the unblinded monitor to assure that re-supply requests have been 
noted. 
3K3A-APC is supplied as a frozen, sterile, non-pyrogenic, citrate-buffered, hypertonic solution for 
intravenous infusion with a total extractable volume of 5.0 mL. Each vial contains 5.0 mg of 3K3A-
APC drug substance, 25.8 mg of sodium citrate, 87.7 mg of sodium chloride, 1 mg of polysorbate-
80 in 5 mL of water for injection.  The vials are sealed with FluroTec® stoppers that are secured 
with Flip-Off® overseals.  No preservatives or bacteriostatic agents are added.   
Vials are labeled as shown in Figure 4 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: 
3K3A-APC Label 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 37 of 81 
 
 
 
 
 
 
 
 
 
5.1.2 
Placebo 
Placebo will be 0.9% sodium chloride in water in 100 mL infusion bags.  Clinical sites will be 
responsible for supply of 0.9% sodium chloride infusion bags for administration of study drug and 
placebo. 
5.2 
Storage of Study Drug 
3K3A-APC vials must be stored at ≤-60°C to ≥-90°C.  The study drug should be maintained in a 
secure, limited-access room and in an alarmed, temperature-controlled freezer. If the temperature 
exceeds -60C for longer than 1 hour, or cumulatively 8 hours in a 30-day period, the Sponsor 
should be contacted. Temperature logs should be submitted to the assigned pharmacy monitor for 
interim remote monitoring and must be available during monitoring visits. 
5.3 
Preparation and Blinding of Study Drug 
Subjects will be randomized using an IWRS to either 3K3A-APC or placebo (in a 3:1 ratio; however, 
during safety review pauses only placebo subjects will be enrolled). The treatment allocation will 
be made available to the designated unblinded site pharmacist by the IWRS.  Each subject will 
receive up to 5 doses of 3K3A-APC or placebo according to the randomization schedule.  Blinding 
will be controlled by administering the same volume to all subjects (i.e., the entire 100-mL infusion 
bag). Four possible dose levels of 3K3A-APC will be considered for evaluation in this study: 120, 
240, 360 and 540 μg/kg. 
Under sterile conditions, 3K3A-APC will be prepared as follows: 
1. Calculate the volume of 3K3A-APC to be administered to the subject and remove the 
appropriate number of vials from the freezer. 
2. Thaw the vials for approximately 15 minutes at room temperature, or until completely 
thawed. Accelerated heating methods should not be used. 
3K3A-APC Injection, 1.0 mg/mL, 5.0 mL 
 
Lot # XXXXXXXX; Mfg Date: MMM YYYY 
 
Storage: ≥ -90˚C, < -60ºC, protected from light 
 
For intravenous injection –Single use only 
 
Instructions for Use: Refer to Protocol 
 
 
Caution: New Drug—Limited by United States Law to Investigational Use. 
 
ZZ Biotech, LLC, Houston, TX, 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 38 of 81 
3. Remove the calculated volume of 0.9% sodium chloride in water from the 100 mL 
infusion bag. 
4. Remove the calculated volume of 3K3A-APC from the thawed vial(s). 
5. Add the 3K3A-APC to the infusion bag. 
Placebo will be administered as 0.9% sodium chloride in water, 100 mL. 
Refer to the current ‘Drug Storage, Handling and Administration Manual’ for further instructions 
and examples; the Drug Storage, Handling and Administration Manual will always supersede the 
study drug handling instructions in this protocol. 
5.4 
Administration of Study Drug 
Study drug will be infused into a large bore peripheral arm vein at a rate of 400 mL/hr over 15 
minutes for all dose levels. The first dose of study drug will be administered 30 to 120 minutes after 
tPA has completed or mechanical thrombectomy begins (arterial puncture), whichever is sooner. 
Subsequent doses of study drug should be given every 12 hours (+/- 1 hour) for 5 total doses (or 
until discharge, whichever occurs first). It is preferable not to skip doses of study drug, and should 
a dose need to occur outside of the +/- 1-hour window (which will be reported as a protocol 
deviation), doses should never be given within 8 hours of one another. Please note that PK samples 
should be drawn from the opposite arm. See ‘Drug Storage, Handling and Administration Manual’ 
for further instructions on administration. 
After the study drug infusion is complete, the IV line should be flushed with at least 20 mL of normal 
saline to ensure complete administration of the residual study drug. The calendar date, 24-hour 
clock time of the beginning and end of the infusion, and the volume infused should be recorded for 
capture in the CRF.   
5.5 
Accountability of Study Drug 
In accordance with local regulatory requirements, the Investigator, designated site staff, or head of 
the medical institution (where applicable) must document the amount of investigational product 
dispensed and/or administered to study subjects, the amount received from the central pharmacy, 
and the amount destroyed upon completion of the study. The local PI is ultimately responsible for 
ensuring product accountability records are maintained throughout the course of the study; 
however this responsibility should be delegated to the unblinded study pharmacist(s) for the 
purposes of maintaining the study blind throughout the study. The inventory will include details of 
3K3A-APC received and dispensed to subjects, including the lot number and subject ID. All used 
and unused vials must be kept until reconciliation of delivery records with accountability logs by the 
monitor (unless alternative handling is approved by the CCC due to Institutional policy). After the 
monitor has performed accountability, the site will be instructed by the CCC or designee to either 
destroy the remaining study drug or return it to the Central Pharmacy or manufacturer. An 
accounting must be made of any drug deliberately or accidentally destroyed. Discrepancies 
between the amount of 3K3A-APC received and dispensed must be reconciled and documented. 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 39 of 81 
5.5.1 
Required Concomitant Medications/Interventions 
 
Subjects will become eligible for this clinical study upon initiation of tPA or decision to begin 
mechanical thrombectomy, subject to fulfillment of the study inclusion and exclusion criteria.  The 
administration of tPA should follow the American Heart Association’s national accepted published 
guidelines14. Use of mechanical thrombectomy should follow the local Institutional protocol, and 
should only include the use of FDA approved thrombectomy devices.  
The PK of tPA in stroke patients has not been published; however, the PK can be extrapolated 
from data widely available in acute myocardial infarction (AMI). The tPA label for AMI states that 
the CL is ~475 mL/min and the t½ is ~5 min8, therefore V is ~3,400 mL. Assuming a one-
compartment model and a 90 mg dose (with 10%, 9 mg, given over the 1st minute and the remaining 
81 mg given from 1 to 59 minutes for a total dosing time of 60 minutes), the simulated concentration-
time profile is shown in Figure 5. 
Figure 5:   
Simulated Concentration-Time Profile of tPA in Stroke 
 
The steady-state concentration (Css), 2.9 µg/mL, is consistent with data in the literature for a 
regimen in AMI resulting in a Css of 3.2 ± 0.84 µg/mL based on an immunochemical assay 
(measurement of protein, not activity).  As expected, activity was lower: 2.1 ± 0.23 µg/mL. An 
estimate of true variability can be based on published data, where the %CV of the steady-state 
protein and activity were 26% and 11%, respectively48.  Assuming a similar variability for the stroke 
regimen, the steady-state protein and activity would be 2.9 ± 0.75 µg/mL and 1.9 ± 0.21 µg/mL, 
respectively.  If a 95% confidence interval is assumed, the upper limits would be ~4.5 and ~2.3 
µg/mL, respectively. Steady-state concentration is achieved by 20 to 25 minutes. 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 40 of 81 
5.5.2 
Prohibited Medications and Interventions 
Medications: 
The use of anticoagulants such as vitamin K antagonists, factor Xa inhibitors and thrombin 
inhibitors are prohibited from the time of randomization to 4 hours following the last dose of 3K3A-
APC. Anti-platelet medication must be started in all patients unless clinically contraindicated, e.g., 
hemorrhagic transformation, within 24 hours of admission.  Note: the use of unfractionated or low 
molecular-weight heparin in accordance with standard of care for the prevention of DVT, or heparin 
used to maintain catheter patency, is allowed.  Heparin used during mechanical thrombectomy 
should not exceed 8,000 USP Heparin units unless clinically required for patient safety.  Should a 
subject receive a prohibited medication or undergo a prohibited procedure during the dosing period 
(Days 1 to 3), the PPI will be consulted as to whether to continue treating the subject with remaining 
doses or discontinue the subject from the study drug. 
Interventions: 
No empiric or experimental treatment will be allowed during the study period (90 days). Elective 
procedures should generally be avoided during the study period, unless required for patient 
safety.

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 41 of 81 
 
6 
STUDY PROCEDURES 
6.1 
Schedule of Activities 
Procedure 
Screen/ 
Pre- 
Dose 1 
Study 
Day 15 
Study 
Day 25 
Study 
Day 35 
Study 
Day 46 
Study 
Days 5-
66 
Study Day 
7, or 
Discharge 
+/-3 days  
Study 
Day 14 
+/-4 
days 
Study 
Day 30 
+/-5 
days 
Study 
Day 
90 
+/-10 
days 
tPA Administration or Mechanical 
Thrombectomy1 
SOC 
 
 
 
 
 
 
 
 
 
Informed Consent2 
X 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
X 
 
 
 
 
 
 
 
 
 
Medical History 
SOC 
 
 
 
 
 
 
 
 
 
Weight3 
X 
X3 
 
 
 
 
 
 
Acute Blood Pressure 
Monitoring4 
SOC 
SOC 
 
 
 
 
 
 
 
 
Vital Signs7 
SOC 
X 
X 
X 
SOC 
SOC 
X 
 
X 
X 
Physical Exam 
SOC 
 
SOC 
SOC 
SOC 
SOC 
X 
 
X 
X 
Neurologic Exam: NIHSS8 
X 
 
X 
X 
X 
X 
X 
 
X 
X 
Modified Rankin Scale 
X 
 
 
 
 
 
 
 
X 
X 
Barthel Index 
 
 
 
 
 
 
 
 
X 
X 
Brain Imaging (CT or MRI)9 
SOC 
 
SOC 
 
 
 
 
 
 
 
Brain Imaging (MRI)10 
 
 
 
 
 
 
X 
 
X 
X 
Serum Chemistry11 
SOC / X 
 
X 
X 
X 
 
 
 
 
 
CBC12  
SOC 
 
X 
X 
X 
 
 
 
 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 42 of 81 
Procedure 
Screen/ 
Pre- 
Dose 1 
Study 
Day 15 
Study 
Day 25 
Study 
Day 35 
Study 
Day 46 
Study 
Days 5-
66 
Study Day 
7, or 
Discharge 
+/-3 days  
Study 
Day 14 
+/-4 
days 
Study 
Day 30 
+/-5 
days 
Study 
Day 
90 
+/-10 
days 
Coagulation Studies13 
SOC 
X 
X 
X 
 
 
 
 
 
 
Urinalysis – Dipstick14 
X 
 
X 
X 
X 
 
 
 
 
 
Pregnancy Test15 
X 
 
 
 
 
 
 
 
 
 
ECG 
SOC 
X16 
 
 
 
 
 
 
3KA-APC Plasma Antibody 
X 
 
 
 
 
 
 
X 
X 
 
Blood for PK 
 
X17 
 
 
 
 
 
 
Study Drug Administration18 
 
X 
X 
X 
 
 
 
 
 
 
AE Assessment 
 
X 
X 
X 
X 
X 
X20 
 
X19,20  
SAEs 
only 
 
Con Med Assessment 
 
X 
X 
X 
X 
X 
X20 
 
X19,20 
 
DLT Assessment Confirmation 
 
 
 
 
 
 
X 
 
 
 
Discharge Medications 
 
 
 
 
 
 
X 
 
 
 
1 tPA or Mechanical Thrombectomy: Subjects will be eligible to consent for this study following initiation of tPA administration or the decision to 
begin mechanical thrombectomy, whichever occurs sooner. 
2 Informed consent: Informed consent (and re-consent, as applicable) must be obtained by the CSS PI or a qualified designee (licensed 
physician investigator) listed on the FDA Form 1572. If informed consent was originally provided by a legally authorized representative, and, in 
the opinion of the CSS PI, the subject’s mental status improves sufficiently to enable him/her to provide informed consent, the subject must be 
re-consented in person at the current or next study visit. Re-consenting once the subject regains capacity is an expected part of Good Clinical 
Practice (GCP). 
3Weight: Every effort should be made to obtain an actual pre-dose weight for each subject, as all investigational doses will be based on this 
weight. If a subject’s weight was estimated for the purposes of study drug dose calculation, then an actual weight must be obtained within 24 
hours of dose 1. For those sites participating in the PK study, an actual weight must also be recorded on the day of PK sampling. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 43 of 81 
4Acute Blood Pressure Monitoring: SOC tPA blood pressure monitoring requires that for the first 24 hours after starting treatment, collection is: 
every 15 minutes for 2 hours after starting the infusion, then every 30 minutes for 6 hours, then every hour for 18 hours.  The eCRF will capture 
one hourly time point for the first 24 hours. For subjects who undergo mechanical thrombectomy only, one hourly time point for the first 24 hours 
must be captured. 
5Days 1-3: If a subject is discharged prior to receiving all 5 doses of study drug, then further dosing will be halted and the subject should be seen 
for Day 7 assessments.  
6 Day 4-6 Assessments: Only required if the subject remains inpatient. 
7 Vital Signs: Heart rate, respiratory rate, blood pressure, oxygen saturation and temperature should be collected daily during the first 6 days 
(SOC), and on the Day 7, 30 and 90 visits. In addition, following each 3K3A-APC infusion, vital signs should be collected just prior to and at end 
of infusion (EOI) and every hour for 4 hours (+/- 30 minutes). Temperature at EOI is not required.  
8 NIHSS/Days 4-6: If a subject remains inpatient on Days 4-6, a NIHSS should be collected daily, and any other available data will be collected in 
the eCRF. 
9 Brain Imaging: As per local standard of care, CT or T1 MRI must be performed at baseline and 24-36 hours following tPA bolus administration. 
Note that MRI may be used in place of CT for the baseline scan only if the site receives prior approval from the CCC. 
10 Brain Imaging: 1.5T MRI examination to include—at minimum—T1 and T2 weighted images, as well as DWI and SWI sequences must be 
performed for all subjects on Day 7 (or just prior to discharge, whichever occurs first), Day 30 and Day 90. Changes to the protocol-specified MRI 
criteria that receive prior approval by the PPI will not be considered protocol deviations. While MRI is preferred at Day 90, should a subject 
become unable to undergo MRI, a CT scan should be performed. 
11 Chemistry: Perform liver function, glucose and electrolytes. 
12 CBC: Perform a complete blood count with platelets; a differential must be performed if the white blood cell count is elevated (above the site’s 
ULN). 
13 Coagulation: Perform aPTT, PT, INR and fibrinogen. For each 3K3A-APC dose, samples should be drawn and processed pre-dose (window 
varies; see below) and 1 hour post-dose (+/- 15 minutes). For doses 2-5 the pre-dose window is within 60 minutes prior to the start of the 
infusion. For dose 1 however, note that some of these pre-dose assessments are required for screening and they should all be prior to tPA (in 
those subjects who receive tPA). Therefore, the pre-dose draw for dose 1 may be more than 60 minutes prior to the infusion. If the pre-dose 
samples for dose 1 are drawn after tPA they should not be drawn until at least 20 minutes has passed since tPA finished so as to minimize tPA’s 
effect on the laboratory results.  
14 Urinalysis: Microscopic urinalysis must be performed if dipstick is positive for RBCs. 
15 Pregnancy Test: Serum or urine pregnancy test for women of child-bearing potential only. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 44 of 81 
16 ECG: One post-dose ECG should be collected at ‘end of infusion’ (Cmax) (+ 5 minutes).  The Investigator can decide which dose, 1-5, will be 
used for ECG collection. 
17 PK Samples: PK samples will be collected from subjects at a subset of participating sites; samples will be collected following one of the doses 
of 3K3A-APC at the following time points: end of infusion, 20, 40, 60 and 80 minutes post-dose. The Investigator can decide which dose, 2-5, 
will be used for PK collection. 
18 Study Drug Administration: 3K3A-APC (or placebo) will be administered as a 15-minute infusion every 12 hours for 5 doses, or until 
discharge.  The first dose of study drug (or placebo) should be started 30 to 120 minutes following completion of tPA or initiation of mechanical 
thrombectomy (arterial puncture), whichever occurs sooner.  Subsequent doses should be given every 12 hours (+/- 1 hour) for 5 total doses (or 
until discharge). Dose 1 must be confirmed in the data system within 2 hours of infusion time. 
19 SAE and Con Med Collection after Day 7: SAEs will be collected and reported out to actual study Day 30.  Should a SAE be reported between 
Day 7 and Day 30, then all Con Meds through Day 30 need to be reported in the eCRF. 
20 Ensuring Complete Data Collection: Should the Day 7 or Day 30 visit occur on the early side of the allowed window, a phone call is required 
and should be documented to ensure that all AEs are captured through actual Day 7, and SAEs through actual Day 30, along with the required 
concomitant medications.   

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 45 of 81 
 
6.2 
Schedule of Activities: Study Drug Infusion Detail 
 
Dose 1 
Doses 2-55 
Procedure 
Pre 
During 
Post 
Pre 
During 
Post 
tPA Administration or 
Mechanical Thrombectomy1 
SOC 
 
 
 
 
 
Informed Consent2 
X 
 
 
 
 
 
Inclusion/Exclusion 
X 
 
 
 
 
 
Medical History 
SOC 
 
 
 
 
 
Weight3 
X 
 
X 
X3 
1x, PK day only 
Acute Blood Pressure 
Monitoring4 
SOC 
SOC 
SOC 
 
 
 
Vital Signs6 
SOC/ X 
 
X 
X 
 
X 
Physical Exam 
SOC 
 
 
SOC 
1/day 
Neurologic Exam: NIHSS7 
X 
 
 
X7 
1/day unless clinically 
indicated 
Modified Rankin Scale 
X 
 
 
 
 
 
Barthel Index 
 
 
 
 
 
 
Brain Imaging (CT or MRI) 8  
SOC 
 
 
SOC  
1x only, 24-36 hrs post tPA 
Serum Chemistry9 
SOC / X 
 
 
X 
1/day 
CBC10  
SOC 
 
 
X 
1/day 
Coagulation Studies11 
SOC 
 
X 
X 
 
X 
Urinalysis – Dipstick12 
X 
 
 
X 
1/day 
Pregnancy Test13 
X 
 
 
 
 
 
ECG 
SOC 
 
X14 
1 dose 
only 
 
 
X14 
1 dose 
only 
3KA-APC Plasma Antibody 
X 
 
 
 
 
 
Blood for PK 
 
 
 
 
 
X15 
1 dose 
only 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 46 of 81 
 
Dose 1 
Doses 2-55 
Procedure 
Pre 
During 
Post 
Pre 
During 
Post 
Study Drug Administration16 
 
X 
 
 
X 
 
AE Assessment 
X 
X 
Con Med Assessment 
X 
X 
1 tPA or Mechanical Thrombectomy: Subjects will be eligible to consent for this study following 
initiation of tPA administration or the decision to begin mechanical thrombectomy, whichever 
occurs sooner. 
2 Informed consent: Informed consent (and re-consent, as applicable) must be obtained by the 
CSS PI or a qualified designee (licensed physician investigator) listed on the FDA Form 1572. If 
informed consent was originally provided by a legally authorized representative, and, in the 
opinion of the CSS PI, the subject’s mental status improves sufficiently to enable him/her to 
provide informed consent, the subject must be re-consented in person at the current or next 
study visit. Re-consenting once the subject regains capacity is an expected part of Good 
Clinical Practice (GCP) 
3 Weight: Every effort should be made to obtain an actual pre-dose weight for each subject, as all 
investigational doses will be based on this weight. If a subject’s weight was estimated for the 
purposes of study drug dose calculation, then an actual weight must be obtained within 24 
hours of dose 1. For those sites participating in the PK study, an actual weight must also be 
recorded on the day of PK sampling. 
4 Acute Blood Pressure Monitoring: SOC tPA blood pressure monitoring requires that for the 
first 24 hours after starting treatment, collection is: every 15 minutes for 2 hours after starting 
the infusion, then every 30 minutes for 6 hours, then every hour for 18 hours. The eCRF will 
capture one hourly time point for the first 24 hours. For subjects who undergo mechanical 
thrombectomy only, one hourly time point for the first 24 hours must be captured. 
5 Day 3: If a subject is discharged prior to receiving all 5 doses of study drug, then further dosing 
will be halted and the subject should be seen for Day 7 assessments.  
6 Vital Signs: Heart rate, respiratory rate, blood pressure, oxygen saturation and temperature 
should be collected daily during the first 6 days (SOC).  In addition, following each 3K3A-APC 
infusion, vital signs should be collected just prior to and at end of infusion (EOI) and every hour 
for 4 hours (+/- 30 minutes). Temperature at EOI is not required. 
7 NIHSS: A NIHSS should be collected daily, or more frequently when clinically indicated. 
8 Brain Imaging: As per local standard of care, CT or T1 MRI must be performed at baseline and 
24-36 hours following tPA bolus administration. Note that MRI may be used in place of CT for 
the baseline scan only if the site receives prior approval from the CCC. 
9 Chemistry: Perform liver function, glucose and electrolytes. 
10 CBC: Perform a complete blood count with platelets; a differential must be performed if the 
white blood cell count is elevated (above the site’s ULN). 
11 Coagulation: Perform aPTT, PT, INR and fibrinogen. For each 3K3A-APC dose, samples 
should be drawn and processed pre-dose (window varies; see below) and 1 hour post-dose (+/- 
15 minutes). For doses 2-5 the pre-dose window is within 60 minutes prior to the start of the 
infusion. For dose 1 however, note that some of these pre-dose assessments are required for 
screening and they should all be prior to tPA (in those subjects who receive tPA). Therefore, the 
pre-dose draw for dose 1 may be more than 60 minutes prior to the infusion. If the pre-dose 
samples for dose 1 are drawn after tPA they should not be drawn until at least 20 minutes has 
passed since tPA finished so as to minimize tPA’s effect on the laboratory results. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 47 of 81 
12 Urinalysis: Microscopic urinalysis must be performed if dipstick is positive for RBCs. 
13 Pregnancy Test: Serum or urine pregnancy test for women of child-bearing potential only. 
14 ECG: One post-dose ECG should be collected at ‘end of infusion’ (Cmax) (+ 5 minutes).  The 
Investigator can decide which dose, 1-5, will be used for ECG collection. 
15 PK Samples: PK samples will be collected from subjects at a subset of participating sites; 
samples will be collected following one of the doses of 3K3A-APC at the following time points: 
end of infusion, 20, 40, 60 and 80 minutes post-dose. The Investigator can decide which dose, 
2-5, will be used for PK collection. 
16 Study Drug Administration: 3K3A-APC (or placebo) will be administered as a 15-minute 
infusion every 12 hours for 5 doses, or until discharge.  The first dose of study drug (or placebo) 
should be started 30 to 120 minutes following completion of tPA or initiation of mechanical 
thrombectomy (arterial puncture), whichever occurs sooner.  Subsequent doses should be 
given every 12 hours (+/- 1 hour) for 5 total doses (or until discharge). Dose 1 must be 
confirmed in the data system within 2 hours of infusion time. 
 
 
 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 48 of 81 
6.3 
Timing of Study Activities 
6.3.1 
Screening/Pre-Randomization Evaluations/procedures 
Screening procedures are described in Section 4.4. 
6.3.1.1.1 
Admission/Standard of Care Procedures 
The following procedures will be performed upon arrival of the stroke team (those marked with an 
asterisk* will be collected in accordance with standard of care and are expected to be performed 
prior to tPA, mechanical thrombectomy and informed consent): 
• Medical history and PE*  
• Assessment of Baseline Medications (all medications taken within 3 days prior to tPA 
administration)* 
• Vital signs (blood pressure, heart rate, temperature, respiratory rate, oxygen saturation)* 
• Body weight* 
• Non-contrast enhanced head CT* or MRI (if preapproved) 
• Neurological examination: NIHSS* 
• 12-lead electrocardiogram (ECG)* 
Laboratory Tests:  
• CBC (complete blood count and platelets)* 
• Chemistries (liver function, glucose and electrolytes)* 
• Coagulation (PT, aPTT, INR, fibrinogen)* 
• Urinalysis (dipstick or microscopic, per SOC)* 
Patients who meet the criteria for tPA administration or mechanical thrombectomy or both (see 
Section 5.5.1) will be considered for participation in this protocol. The administration of tPA should 
follow the American Heart Association’s national accepted published guidelines14. Use of 
mechanical thrombectomy should follow the local Institutional protocol, and should only include the 
use of FDA-approved thrombectomy devices.  Note that MRI may be used in place of CT for 
standard of care imaging prior to tPA/mechanical thrombectomy only if the site receives prior 
approval from the CCC.  
The AHA Guidelines recommend assessing PTT, INR, and fibrinogen prior to administering tPA14. 
Eligibility for enrollment in this study is based on PTT and INR levels. So as to have an accurate 
reflection of the subject’s true baseline, the pre-dose 1 blood draws for coagulation assessments 
should occur as SOC prior to tPA for patients receiving tPA. If that is not done for some reason, 
then the pre-dose 1 blood draw should occur at least 20 minutes after tPA completion, in order to 
minimize tPA’s effect on the levels.  

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 49 of 81 
6.3.1.2 Informed Consent 
Once the patient begins tPA administration or the decision to begin mechanical thrombectomy is 
made, whichever occurs sooner, he/she can be presented with the consent form and evaluated for 
study enrollment. Refer to Section 4.4.3 for details on the consenting process.   
6.3.1.3 Slot Assignment and Randomization  
Following consent of the subject, or his/her legally authorized representative, the following 
assessments should be performed: 
• Estimated pre-stroke mRS (to determine study eligibility) 
• A pregnancy test in women of child bearing potential (serum or urine, per Investigator’s 
discretion) will be required to qualify the eligibility of female patients. 
• An actual pre-dose weight for each subject is preferred, as all investigational doses will be 
based on this weight. If a subject’s weight was estimated for the purposes of study drug 
dose calculation, then an actual weight must be obtained within 24 hours of dose 1. 
Subjects who have signed consent (or whose representatives have provided surrogate consent) 
and meet all inclusion and exclusion criteria can be randomized into the study; randomization will 
be managed electronically via the IWRS. The Investigator, or designee, should randomize the 
subject in the IWRS to receive the unique subject number, which will also be linked to the allocated 
treatment assignment (blinded to clinical staff). Subjects who will receive mechanical thrombectomy 
only should be randomized close to the start of the procedure (arterial puncture) to ensure that they 
continue to meet eligibility. 
The unblinded pharmacist(s) will receive the treatment assignment from the IWRS that will be used 
to prepare the investigational treatment as described in Section 5.3. 
It is important to confirm eligibility again close to investigational dose 1 as the NIHSS score may 
drop below 5 during the time between randomization and the first dose of study drug. For this 
reason, a repeat NIHSS should be assessed: 
• 
Immediately prior to Dose 1 infusion if the subject received tPA treatment only, or  
• 
Immediately prior to draping the subject in preparation for mechanical thrombectomy if 
the subject is to receive mechanical thrombectomy alone or in combination with tPA. 
If the new NIHSS score has improved such that the subject is no longer eligible (repeat NIHSS<5) 
do not administer study drug. Submit the termination form and other required documents so that 
this subject can be replaced in the cohort. Refer to the NN104 ‘Manual of Operations’ for more 
detail. Randomized subjects who experience significant neurologic improvement (defined as a 
NIHSS score <5) prior to receipt of study drug will be termed 'Early Responders' and will not be 
included in the study. ‘Early Responders’ will not be followed, and will be replaced in the CRM.  Any 
subject who receives any amount of study drug will be considered "Dosed" and will be followed to 
the end of the study. 
6.3.2 
On-Study Evaluations/procedures 
6.3.2.1.1 
Study-Specific Baseline Procedures 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 50 of 81 
Once a subject has been randomized into the study, the following will be performed prior to receipt 
of the investigational treatment: 
• Chemistry (liver function, if not obtained during SOC pre-tPA work-up) 
• Blood for serum antibody sample (‘pre-dose’) 
• ‘Pre-dose’ vital signs (blood pressure, heart rate, temperature, respiratory rate, oxygen 
saturation) 
6.3.2.1.2 
Study-Specific Post-Treatment Procedures 
Investigational Dose #1: 
The first investigational dose of study drug should be started 30 to 120 minutes following 
completion of tPA or initiation of mechanical thrombectomy (arterial puncture), whichever occurs 
sooner. 
After administration of 100 mL of investigational treatment, the following should be performed: 
• Vital signs (blood pressure, heart rate, temperature, respiratory rate, oxygen saturation) 
should be collected at end of infusion (EOI) and approximately every hour (+/- 30 minutes) 
for 4 hours, then per local SOC.  Temperature at EOI is not required. 
NOTE: the NINDS tPA protocol should guide vital sign collection following tPA administration; 
therefore, actual collection may be more frequent than what will be captured for this study 
protocol. The eCRF will capture one hourly time point for the first 24 hours. For subjects who 
undergo mechanical thrombectomy only, one hourly time point for the first 24 hours must be 
captured. 
• Blood for coagulation (PT, aPTT, INR, fibrinogen) should be collected 1 hour after EOI (+/- 
15 minutes).  
• One post-dose ECG should be collected at EOI (Cmax) (+ 5 minutes).  The Investigator can 
decide which dose, 1-5, can be used for ECG collection. Since the ECG collection is 
flexible, it should be planned well in advance so that it is collected as close to EOI as 
possible. Should the ECG window be missed, it is preferred to defer the collection to the 
next planned investigational dose. 
Investigational Doses #2-5: 
Subjects should receive 100 mL of investigational treatment every 12 hours (+/- 1 hour) for up to 5 
total doses (refer to section 5.4). Subjects will only receive investigational treatment for as long as 
they remain as an inpatient. The following should be performed: 
• Vital signs should be collected just prior to infusion, at EOI and approximately every hour 
(+/- 30 minutes) for 4 hours, then per local SOC 
• Blood for coagulation (PT, aPTT, INR, fibrinogen) should be collected from the arm 
opposite the infusion: 
o 
Prior to each infusion (within 60 minutes of infusion) 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 51 of 81 
o 
1 hour after EOI (+/- 15 minutes)  
• If not collected previously, one post-dose ECG should be collected at EOI (Cmax) (+ 5 
minutes). The Investigator can decide which dose, 1-5, can be used for ECG collection. 
Since the ECG collection is flexible, it should be planned well in advance so that it is 
collected as close to EOI as possible. Should the ECG window be missed, it is preferred to 
defer the collection to the next planned investigational dose. 
Investigational Dose #2-5 - Pharmacokinetics (performed at a sub-set of sites): 
Blood for plasma PK samples must be collected from the arm opposite the infusion: 
• 
EOI (“post-dose: 0”) 
• 
20 minutes after EOI (“post-dose: 20m”) 
• 
40 minutes after EOI (“post-dose: 40m”) 
• 
60 minutes after EOI (“post-dose: 60m”) 
• 
80 minutes after EOI (“post-dose: 80m”) 
The Investigator can decide which dose, 2-5, will be used for PK collection. PK samples should 
only be collected following one dose of study drug. 
6.3.2.1.3 
Study-Specific Daily Procedures, Days 2-6 
Study Day 1 will be defined as the first 24-hour period during which Infusion #1 is given. For 
example, if admission occurs at 11:55 PM and the first investigational infusion occurs at 1:00 AM, 
then Day 1 will begin at 12:00 AM, and admission would be considered Day 0. Every subject 
enrolled will have a different investigational treatment schedule based on the time of tPA or 
mechanical thrombectomy and the subsequent first dose of 3K3A-APC or placebo. Procedures that 
center around the administration of investigational product may not fall on a specific study day, and 
therefore are outlined in section 6.3.2.2. The following procedures should be performed daily, or as 
indicated: 
Daily 
• PE (only notable changes from baseline must be recorded) 
• Assessment of AEs 
• Assessment of Concomitant Medications 
• Vital signs, and as indicated in section 6.3.2.2 around investigational treatment 
• Neurological examination: NIHSS 
Laboratory Tests:  
• CBC (complete blood count and platelets), Days 2-4 only; a differential must be performed 
if the white blood cell count is elevated. 
• Chemistries (liver function, glucose and electrolytes), Days 2-4 only 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 52 of 81 
• Urinalysis (dipstick or microscopic), Days 2-4 only; microscopic urinalysis must be 
performed if dipstick is positive for RBCs. 
Once Only 
• Non-contrast enhanced head CT or T1 MRI, per SOC, 24-36 hours following tPA bolus 
administration.  
NOTE: If a CSS uses MRI as SOC at this time point, it is encouraged that the MRI protocol for 
this study be used. Refer to the ‘Imaging Plan’ for details. 
6.3.2.1.4 
Study-Specific Procedures, Day 7 or Discharge (+/- 3 day window) 
• PE (only notable changes from baseline must be recorded) 
• 1.5T MRI: T1 and T2 weighted images, as well as DWI and SWI sequences 
• Assessment of AEs (through actual Day 7 only) 
• Assessment of Concomitant Medications (through actual Day 7 only) 
NOTE: Should the Day 7 visit occur on the early side of the allowed window, a phone call is 
required and should be documented to ensure all AEs are captured through actual Day 7 along 
with the required concomitant medications.  Concomitant medications must also be collected 
through Day 30 only when a SAE occurs on or before actual Day 30.  
• Assessment of Discharge Medications (medications that the subject is sent home with 
when discharged from the hospital)     
• Vital signs (blood pressure, heart rate, temperature, respiratory rate, oxygen saturation) 
• Neurological examination: NIHSS 
6.3.2.1.5 
Study-Specific Procedures, Day 14 (+/- 4 day window) 
• Blood for serum antibody sample (‘post-dose D14’) 
NOTE: Every effort should be made to ensure the subject is seen on Day 14 in order to collect 
the antibody sample. The CSS coordinator should contact the CCC to discuss alternative options 
available to sites for subjects who are unable to return to the CSS. 
6.3.2.2 Study-Specific Procedures, Day 30 (+/- 5 day window) 
• PE (only notable changes from baseline must be recorded) 
• 1.5T MRI: T1 and T2 weighted images, as well as DWI and SWI sequences 
• Assessment of SAEs (through actual Day 30 only) 
• If a SAE is reported, assessment of Concomitant Medications  
NOTE: Should the Day 30 visit occur on the early side of the allowed window, a phone call is 
required and should be documented to ensure all SAEs are captured through actual Day 30 along 
with the required concomitant medications.   

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 53 of 81 
• Vital signs (blood pressure, heart rate, temperature, respiratory rate, oxygen saturation) 
• Neurological examination: NIHSS 
• mRS  
• BI 
• Blood for serum antibody sample (‘post-dose D30’) 
6.3.2.3 Study-Specific Procedures, Day 90 (+/- 10 day window) 
• PE (only notable changes from baseline must be recorded) 
• Vital signs (blood pressure, heart rate, temperature, respiratory rate, oxygen saturation) 
• Neurological examination: NIHSS 
• mRS  
• BI 
• 1.5T MRI: T1 and T2 weighted images, as well as DWI and SWI sequences 
NOTE: While MRI is preferred at Day 90, should a subject become unable to undergo MRI, a CT 
scan should be performed. 
6.4 
Special Instructions and Definitions of Evaluations 
6.4.1 
Protocol Deviations and Violations 
The site monitor is responsible for collection of all protocol deviations that occur during the course 
of the study to ensure proper reporting in the clinical study report.  
Generally, any activity that is not performed as outlined in the protocol should be categorized as a 
‘Protocol Deviation’.  Missed visits and any procedures not performed (not attempted) for reasons 
other than illness, injury or progressive disability (i.e., subject is physically unable to perform test) 
will be reported as protocol deviations. Procedures or visits not performed due to illness, injury or 
disability, including procedures that were attempted but failed (i.e., blood samples unable to be 
drawn after multiple attempts, or weight unable to be obtained due to subject immobility) will not be 
reported as protocol deviations. Deviations fall into two categories, ‘major’ and ‘minor’, and are 
defined as follows: 
Major: Any deviation that impacts safety, welfare, or rights of a study subject, or impacts the 
primary outcome of the study (safety assessments). Examples include: Informed Consent issues 
affecting a subject’s rights, Inclusion/Exclusion violations, Missed Assessments affecting safety 
endpoints, Study Drug Administration that affects a study endpoint or the subject’s welfare. A major 
deviation is also termed a protocol violation. 
Minor: Any deviation that does not fall within the above category.  Examples include: Out of 
Window or Missed study assessments that do not affect a study endpoint or the subject’s welfare. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 54 of 81 
6.4.2 
Medical History 
The subject’s medical history should include the standard intake history as well as all AEs 
occurring after signing of the informed consent form, but before the first dose of study drug. 
6.4.3 
Treatment History 
All treatments, including administration of tPA or use of thrombectomy devices, will be recorded in 
the subject’s medical record (source documentation) and in the eCRF. Baseline medications will 
be recorded 3 days prior to tPA or mechanical thrombectomy through just prior to first 
administration of study drug. 
6.4.4 
Concomitant Medications/Treatments 
All medications taken following the first administration of study drug through actual Day 7 will be 
recorded. If a subject experiences a SAE between Day 7 and Day 30, then concomitant 
medications should also be captured through actual Day 30. 
6.4.5 
Discharge Medications 
Discharge medications will be recorded in the medical record and captured in the eCRF and 
should include all medications that the subject is sent home with when discharged from the 
hospital. 
6.4.6 
Protocol Amendments and Study Termination 
All revisions and/or amendments to this protocol must be approved in writing by the Sponsor and 
the CIRB. The Investigator will not make any changes to the conduct of the study or the protocol 
without first obtaining written approval from the Sponsor and the CIRB, except where necessary to 
eliminate an apparent immediate hazard to a study subject. 
The Sponsor and NeuroNEXT Network reserve the right to discontinue the study at a clinical study 
site(s) for safety or administrative reasons at any time. Should the study be terminated and/or the 
clinical study site closed for any reason, all documentation and study drug pertaining to the study 
must be returned to the Sponsor or its representative.  
6.4.7 
Special Blood Sample Collection and Handling 
6.4.7.1 Pharmacokinetic Sample Collection and Handling (Plasma) 
PK samples will be collected from approximately 40 subjects at a sub-set of study sites to ensure 
adequate sampling across all dose levels.  Samples should be collected following one of the doses 
of 3K3A-APC at the following time points: EOI and 20, 40, 60, 80 minutes after the EOI (5 total 
samples per subject). The Investigator can decide which dose, 2-5, will be used for PK collection. 
Collection of samples outside of the requested nominal time will not be a protocol deviation, but it 
is essential that the actual time of collection be captured for analysis. 
Collection: 
• 
Approximately 4 mL of blood will be collected into Sponsor-provided tubes containing 
sodium citrate and the serine protease inhibitor benzamidine.  
• 
After blood collection, invert gently 8-10 times; samples will be held at room 
temperature pending centrifugation.   

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 55 of 81 
Processing: 
• 
To separate plasma, blood samples will be centrifuged at room temperature within 10 
– 30 minutes at 3000 rpm (2000-4000 x g) for 10 minutes.   
• 
The plasma will be removed from the blood, split into 2 equal aliquots, and stored in 2 
mL labeled Cryotube™ containers.   
• 
Plasma will immediately be placed in a temperature-controlled (with recordings) and 
alarmed ≤ -70˚C freezer. 
Storage: 
• 
Samples will be stored in a ≤ -70˚C freezer at the Investigational site. 
Shipping: 
• 
Frozen samples will be batch shipped on dry ice to the central laboratory at the 
University of Rochester for storage.  Pre-printed air bills and temperature-validated 
packaging will be provided by the central laboratory. Primary and back-up aliquots 
should always be shipped separately in order to mitigate against loss. Refer to the 
‘Laboratory Manual’ for additional detail on the shipping frequency of samples.  
Analysis: 
• 
PK analysis will occur at 
. An 
enzyme capture immunoassay method has been developed and validated by 
 for 
determination of 3K3A-APC activity in plasma. Samples collected for PK will only be 
used for PK-related analysis and method development. 
6.4.7.2 Blood Sample Collection and Handling for Antibody Testing (Serum) 
Blood samples for anti-3K3A-APC antibody analysis will be collected from all subjects just prior to 
receiving the first dose of investigational treatment and again at the Day 14 and Day 30 visits (3 
total samples per subject).  
Collection: 
• 
Approximately 2-3 mL of blood will be collected into standard clot tubes that do not 
contain anticoagulant.   
• 
After blood collection, samples will be held at room temperature for at least 20 minutes 
to allow clotting prior to centrifugation.  However please note that samples must be 
processed within 60 minutes of collection time and divided serum must be 
stored in a ≤ -70˚C freezer within 2 hours of collection time. 
Processing: 
• 
To separate serum, blood samples will be centrifuged at 1500 - 2200 rpm (1500 x g) 
at 2°-8°C for 10-15 minutes.   
• 
The serum will be removed from the blood, split into 2 equal aliquots, and stored in 2 
mL labeled Cryotube™ containers.  

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 56 of 81 
• 
Serum will be immediately placed in a temperature-controlled (with recordings) and 
alarmed ≤ -70°C freezer within 2 hours of collection. 
NOTE: Subjects unable to return to the study site may have blood drawn at an outside medical 
facility or at home. Serum collected outside a medical facility may be placed in a wet ice slurry for 
2-3 minutes and centrifuged at room temperature at 1500 - 2200 rpm (1500 x g) for 10-15 minutes. 
After aliquoting, the serum must be placed on dry ice for transport or shipping to the study site. 
Storage: 
• 
Samples will be stored in a ≤ -70°C freezer at the Investigational site. 
Shipping: 
• 
Frozen samples will be batch shipped on dry ice to the central laboratory at the 
University of Rochester for storage.  Pre-printed air bills and temperature-validated 
packaging will be provided by the central laboratory. Primary and back-up aliquots 
should always be shipped separately in order to mitigate against loss. Refer to the 
‘Laboratory Manual’ for additional detail on the shipping frequency of samples. 
Analysis: 
• 
Antibody analysis will occur at 
 
. A qualitative enzyme-linked immunosorbent assay (ELISA) method has been 
developed and validated by 
 for anti-3K3A-APC antibody detection. Samples 
collected for anti-drug antibody analysis will only be used for antibody-related analysis 
and method development. 
6.4.8 
Questionnaire Certification 
Investigators and designated study staff will be trained and certified to use the NIHSS and the 
mRS, using a recognized certifying agency.  
6.4.9 
Imaging Central Review 
A central reader will review all scans for each subject who receives at least one infusion of study 
drug. Five scans per subject are expected, including two standard of care scans and three study 
mandated scans.  Please refer to the ‘Imaging Plan’ for details.  
7 
MANAGEMENT OF ADVERSE EXPERIENCES 
Expected AEs due to stroke can be estimated from the Virtual International Stroke Trials Archive 
(VISTA)49. In the VISTA dataset, 5775 placebo-treated patients were analyzed. One-hundred-thirty-
two (132) of 756 types of AEs accounted for 82.7% of reported events. Thirty-five (35) of the most 
common types of SAEs are listed below: 
Stroke in evolution 
11.2%1 
Pneumonia 
  5.6% 
Ischemic cerebral infarction 
  4.8% 
Brain edema 
  4.3% 
Cardiac failure 
  3.4% 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 57 of 81 
Myocardial infarction 
  2.9% 
Cerebral hemorrhage 
  2.5% 
Aspiration pneumonia 
  2.5% 
Respiratory failure 
  2.2% 
Hemorrhagic transformation 
  2.2% 
Pulmonary embolism 
  2.0% 
Atrial fibrillation 
  1.8% 
Urinary tract infection 
  1.7% 
Pulmonary edema 
  1.5% 
Cerebrovascular disorder 
  1.5% 
Cardiac arrest 
  1.5% 
Carotid artery disease 
  1.4% 
Sepsis 
  1.3% 
Angina pectoris 
  1.2% 
Hypotension 
  1.1% 
Coma 
  1.1% 
Pyrexia 
  1.1% 
Renal failure 
  1.0% 
Headache 
  0.9% 
ICP increased 
  0.9% 
Respiratory tract infection 
  0.9% 
Bradycardia 
  0.8% 
Transient Ischemic Attack 
  0.8% 
Hypertension 
  0.8% 
Hemorrhagic Cerebral Infarction 
  0.7% 
Somnolence 
  0.7% 
Cerebral Incarceration 
  0.6% 
Deep vein thrombosis 
  0.6% 
Syncope 
  0.5% 
Depression 
  0.5% 
1Shown as percentage of total SAE occurrence; 53 types of SAEs in total were identified. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 58 of 81 
Bacterial pneumonia is one of the most common causes of death in acute stroke patients. 
Reduction of bulbar reflexes, drowsiness, dysphagia, and subsequent aspiration are considered to 
be major contributors to the high incidence of bacterial pneumonia after stroke.50 Recent studies in 
patients with moderate to severe stroke found pneumonia rates between 10.7 and 21%.51-53 
Whether or not the increase in pneumonia rate affects 3-month outcome after stroke is 
controversial.54 Symptomatic ICH occurs in about 6% of patients treated with tPA13. 
8 
STATISTICAL CONSIDERATIONS 
The NeuroNEXT Data Coordinating Center will develop a Statistical Analysis Plan (SAP) in 
collaboration with the protocol principal Investigator and protocol steering committee. 
8.1 
General Design Issues 
8.1.1 
Summary of Study Design 
This is a multicenter, prospective, randomized, controlled, double-blinded Phase 2 study intended 
to evaluate the safety, PK, and preliminary efficacy of 3K3A-APC following administration of tPA, 
or mechanical thrombectomy or both, in patients with moderate to severe acute ischemic stroke.  
The original version of the CRM method proposed enrolling one subject at a time55.  However, 
others have shown that the performance of the CRM may be improved by enrolling cohorts instead 
of a single subject1.  Correspondingly, this study will utilize a modified version of the CRM in order 
to establish a MTD. 
The study will enroll approximately 115 subjects, which includes the planned 88 subjects in groups 
of four (each cohort will include one placebo and three treated subjects) and the additional placebo 
subjects who may be enrolled during safety review pauses.  While placebo is not needed to 
determine the MTD, a placebo group has been included in order to conduct secondary analyses to 
examine for a reduction of pre-clinical tPA/mechanical thrombectomy-related bleeds by central 
read (it is predicted from studies that treatment reduces thrombolysis-related petechial 
hemorrhage).  Subjects will not be considered part of the intent-to-treat (ITT) cohort until they 
receive any amount of 3K3A-APC or placebo.  For example, ‘Early Responders,’ subjects whose 
symptoms resolve between initial randomization and initiation of IMP infusion such that they are no 
longer eligible (repeat NIHSS <5), will be removed from the study and replaced. At any time if 
enrollment is so rapid that two consecutive cohorts are awaiting DLT review, the IWRS will 
randomize any enrolled patients to placebo so as to preserve site-level blinding and trial enrollment 
momentum. These extra placebo treated subjects will enhance the power to detect a change in 
bleed rates for 3K3A-APC-treated subjects. 
Following completion of tPA infusion or initiation of mechanical thrombectomy (arterial puncture), 
whichever occurs sooner, eligible adult subjects will receive 3K3A-APC or placebo 30 to 120 
minutes later given as a 15-minute infusion.  Subjects will receive another 15-minute infusion of 
3K3A-APC every 12 hours (+/- 1 hour) for up to 5 total infusions.  Four dose levels will be 
considered for this study: 120, 240, 360, and 540 µg/kg.  For the purposes of this study, we assume 
an established background symptomatic intracerebral hemorrhage (SICH) rate of 3-6%2-7.  
Correspondingly, the MTD will be defined as the highest dose with a DLT rate of 10% or less.  
Subjects will be enrolled to 3K3A-APC dose cohorts in groups of four (three to specified treatment 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 59 of 81 
dose and one to placebo).  Subjects will generally be enrolled at the dose estimated from the 
assumed dose-response model and prior data to be closest to the MTD.  However, the initial cohort 
will start at the lowest dose level (120 µg/kg) and the dose level may be escalated by no more than 
one dose between consecutive cohorts (there are no restrictions on dose level de-escalation).  
Intra-subject dose modification is not permitted during the study. 
Prior to starting the CRM, based on a best estimate from the literature and previous studies, the 
four dose levels will be assigned prior probabilities as indicated in Table 3 below. 
Table 3. Assumed prior probabilities of toxicity at four dose levels considered for the 
study: 
Dose Level 
120 
240 
360 
540 
Prior Probability of Toxicity 
5% 
7% 
9% 
11% 
 
When designing a CRM, O’Quigley, Pepe and Fisher recommend using a single-parameter dose-
response model 𝜓(𝑥𝑖
∗, 𝑎), which is probability of toxicity at dose 𝑥𝑖
∗ for some unknown parameter, 
𝑎, which defines the shape of the dose-toxicity function.  For this study, a hyperbolic tangent dose-
response model will be used, in which 
𝜓(𝑥𝑖
∗, 𝑎) = {
tanh(𝑥𝑖
∗+1)
2
}
𝑎
. 
After each group of subjects has been treated, and their status observed as to whether or not each 
had a DLT, the posterior mean of 𝑎 will be calculated.  Based upon that estimate, 𝑎̂, the highest 
dose with estimated toxicity probability, 𝜓(𝑥𝑖
∗, 𝑎) less than or equal to 10% will be allocated to the 
next group of subjects needing treatment assignment. If this dose is more than one level higher 
than the previous dose allocated to a cohort, the dose will only be increased one level.  After the 
final group of subjects is enrolled, the final MTD will be defined as the highest dose with estimated 
toxicity probability less than or equal to the target toxicity level of 10%. 
Hence, the design will proceed as follows: 
• 
Enroll the first 4 subjects into cohort 1. 
o 
Treat one of the four subjects (chosen randomly) with placebo. 
o 
Treat the other three subjects with the lowest dose: 120 µg/kg. 
o 
Observe the number of subjects (out of the three treated subjects) that have a 
DLT per study definition. Any given subject who receives only one dose of study 
drug and does not experience a DLT will not be included in the CRM calculation 
(i.e. two or more doses will need to be administered to be included). 
o 
Based upon the observed information from the three treated subjects, refit the 
assumed dose-response curve. 
• 
Initially (through version 7.1. of the protocol), the re-estimated dose-response curve using 
all cohorts enrolled to date was then used to determine the highest dose level of the four 
under consideration that has an estimated probability of toxicity less than or equal to 10% 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 60 of 81 
o 
The next cohort of subjects is treated at the dose level specified above – unless 
the chosen dose level is more than one level higher than the current level.  If so, 
treat the next cohort of subjects at the next dose level above the current level. 
• 
Based on a DSMB recommendation, this process was changed as of version 8.0 of the 
protocol.  The basic process proceeds as described above, but once all subjects in a 
given cohort (n) have been enrolled, data from all prior cohorts (cohort 1, cohort 2, ….., 
cohort n-1) are used to determine the dose level of cohort n+1. 
o 
If enrollment is rapid such that both cohort (n-1) and cohort (n) are filled and 
awaiting DLT review, new subjects enrolled will be randomized to placebo until 
cohort (n-1) has been reviewed. (For example, if both cohort 13 and 14 are filled 
and awaiting review, subjects will be randomized to placebo until cohort 13 is 
closed and the model is rerun to determine the dose for cohort 15.) 
The MTD will be defined as the dose that would be chosen from the CRM at the final step.  The 
study will stop once the first of the following criteria have been met: 
• 
The maximum number of cohorts (22) has been observed. 
• 
If at any time after half of the cohorts (11) have been observed, two consecutive 
iterations suggest a 15% or higher toxicity rate at the lowest dose (stop for safety) 
• 
If the study proceeds straight to the highest dose, and then observes 9 successive 
cohorts at the highest dose with no observed toxicity (stop and declare highest dose the 
MTD)  
Through simulation it was determined that it would be extremely unlikely to observe no DLTs after 
9 successive cohorts if the true toxicity rate were 10%. Thus, after 9 cohorts we would have 
sufficiently determined that all doses under consideration are safe and stopping early would be 
justified. 
Non-serious adverse events (AEs) will be collected through actual Day 7. More specifically, 
subjects will be evaluated for DLTs from administration of the first dose to 48 hours following the 
last dose of study treatment. Blood samples for PK will be collected from approximately 40 subjects 
at a sub-set of study sites following one of the doses of 3K3A-APC at the following time points: end 
of infusion and 20, 40, 60 and 80 minutes after the end of infusion. Subjects must be seen for 
assessments on Days 7, 14, 30 and 90. MRI scans, including SWI sequences, will be obtained at 
7, 30 and 90 days after stroke. 
A SRC will review the safety data for each potential DLT, and make a final determination as to 
whether or not an incident should be classified as a DLT.  Assignment of the dose for  a cohort will 
not occur until all potential DLTs have been reviewed by the SRC.. 
8.1.2 
Randomization and Blinding 
The NeuroNEXT IWR system will be used to randomize subjects according to the scheme pre-
defined by the DCC and will also serve to inform the unblinded study pharmacist of the treatment 
assignment. Subjects will be randomized to either 3K3A-APC or placebo.  There are 22 groups of 
four subjects planned, but fewer may be enrolled should the study meet either of the early stopping 
criteria. Additionally, if two consecutive cohorts are in the DLT review period, subjects will be 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 61 of 81 
assigned to placebo. The additional placebo subjects will be closely monitored and their enrollment 
may be discontinued should the number enrolled exceed what was planned for the study. Subjects 
will not be considered part of the ITT cohort until they receive any amount of 3K3A-APC or placebo.  
For example, ‘Early Responders,’ subjects whose symptoms resolve between initial randomization 
and initiation of IMP infusion such that they are no longer eligible (repeat NIHSS <5), will be 
removed from the study and replaced. Any given subject who receives only one dose of study drug 
and does not experience a DLT will not be included in the CRM calculation (i.e. two or more doses 
will need to be administered to be included). 
8.2 
Outcomes 
8.2.1 
Primary Outcome (Including Definition) 
The primary objective of the study is to evaluate the safety of multiple ascending intravenous (IV) 
doses of 3K3A-APC following tPA administration or mechanical thrombectomy or both in subjects 
who have experienced moderate to severe acute ischemic stroke.  Safety will be assessed by 
defining dose-limiting toxicities (DLTs), which will be graded using the National Cancer Institute 
(NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 
DLTs will be assessed from the first dose to 48 hours following the last dose of 3K3A-APC (unless 
specified below), and will be defined as any of the following AEs that have an attribution of “related” 
to study treatment (possibly, probably and definitely): 
• 
An activated partial thromboplastin time (aPTT) that reaches 2x the upper limit of normal 
(ULN) at 1 hour post-dose.  The ULN range is defined locally by the site laboratory. 
• 
Symptomatic intracranial hemorrhage (SICH) defined as blood present on CT or MRI 
brain images that is associated with clinical worsening that meets the definition of 
neuroworsening (4 or more point increase in NIHSS; see section 9.4.1.3 for definition) 
and in the opinion of the Investigator represents a clinically significant change that can be 
attributed to the hemorrhage. Subarachnoid hemorrhage that occurs in subjects who 
receive mechanical thrombectomy will NOT be considered a DLT, and instead will be 
evaluated in an exploratory analysis upon study completion.   
• 
Laboratory findings that meet all of the following three components (Hy’s Law): 
o 
≥ 3x ULN of alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) 
o 
Serum total bilirubin (TBL) >2x ULN, without initial findings of cholestasis [serum 
alkaline phosphatase (ALP) activity >2x ULN) 
o 
And, no other reason can be found to explain the combination of increased 
aminotransferase (AT) enzymes and TBL, such as viral hepatitis A, B, or C, pre-
existing or acute liver disease, or another drug capable of causing the observed 
injury. 
• 
Any other bleeding event classified as serious by the Investigator, or any bleeding that 
required the administration of more than 2 units of packed red cells over any two 
consecutive days. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 62 of 81 
• 
Any Grade 3 laboratory value that, in the opinion of the Investigator, is related to study 
treatment.  Refer to CTCAE v4.03 sections relevant to laboratory investigations. 
• 
Any adverse event that in the opinion of the Investigator is related to study treatment and 
leads to cessation of further dosing. 
NOTE: All suspected DLTs will be reviewed by a Safety Review Committee, and those reported 
DLTs that are considered possibly related to study drug but definitely related to another event will 
not be considered DLTs upon final adjudication. An example of such an event would be an elevated 
aPTT following dose 1 in a subject who undergoes mechanical thrombectomy during which heparin 
is administered; the elevated aPTT can be attributed to the heparin and therefore should NOT be 
considered a DLT in this isolated instance. Another example would be the occurrence of 
hypofibrinogenemia in a subject who receives tPA. Low fibrinogen levels can be attributed to tPA, 
and there is a documented rate of occurrence of 11% in subjects receiving tPA8. Furthermore, 
3K3A-APC does not cause a reduction in the level of fibrinogen in plasma and therefore this finding 
should NOT be considered a DLT. 
8.2.2 
Secondary Outcome(s) 
Secondary Outcome #1 (PK Properties):  One secondary objective of this study is to investigate 
the PK properties of 3K3A-APC following tPA administration in stroke subjects.  PK parameters 
following administration of 3K3A-APC in the study will be determined using concentration data 
obtained via the enzyme-immunocapture assay of 3K3A-APC amidolytic activity in plasma.  PK 
parameters will be determined by fitting a compartmental model to each subject’s data.  The mean 
+/- standard error plasma concentration over time by treatment group will be plotted on linear and 
semi-logarithmic axes.  Individual subject observed and model-predicted plasma concentration 
over time by treatment group will be plotted on linear and semi-logarithmic axes.  Descriptive 
statistics of PK parameters will be provided for each dose level.  Additionally, the pharmacokinetic-
pharmacodynamic relationship between the change from baseline in aPTT and the concurrently 
measured 3K3A-APC plasma concentration will be evaluated 1 hour after end of infusion. 
Secondary Outcome #2 (Bleed Rates): Another secondary objective of the study is to evaluate 
the effect of 3K3A-APC on the presence of tPA/mechanical thrombectomy-related bleeding 
(hemorrhage and microbleeds) in the brain as determined by 1.5T MRI at Day 30. Each patient will 
have a MRI examination to include—at minimum—T1 and T2 weighted images, as well as diffusion 
weighted imaging (DWI) and susceptibility weighted imaging (SWI) sequences. Changes to the 
protocol-specified MRI criteria that receive prior approval by the PPI will not be considered protocol 
deviations. Since patients will not necessarily have a baseline MRI, post-recanalization 
microbleeds—defined as hypointensities less than 5mm in diameter seen on SWI—will be counted 
as tPA/mechanical thrombectomy-related only if found within the ischemic territory56. All other areas 
of hypointensity on SWI larger than 5mm diameter will be counted as tPA/mechanical 
thrombectomy-related regardless of the territory in which they are found.  
Exploratory Outcomes:  This study will also include outcome data typically collected in all stroke 
trials, as well as sample collection to assess the immunogenic potential of 3K3A-APC. While the 
sample size is too small to observe meaningful treatment effects, the data allow confirmation that 
outcomes in this trial resemble previously published trials. The following will be collected: 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 63 of 81 
• 
Volume of bleeding (hemorrhage and microbleeds) in the brain as determined by MRI at 
Day 30 
• 
Incidence of subarachnoid hemorrhage in subjects who receive mechanical thrombectomy 
• 
7-day National Institutes of Health Stroke Scale (NIHSS) scores 
• 
90-day modified Rankin Scale (mRS) 
• 
90-day Barthel Index (BI) 
• 
Infarct volume at 90 days (MRI, or CT if unable to obtain MRI) 
• 
Pre-Dose 1, Day 14 and Day 30 anti-drug antibody samples 
8.3 
Sample Size and Accrual 
8.3.1 
Primary Outcome 
In order to assess the adequacy of the sample size, we conducted a simulation study to examine 
the ability of the study to identify the MTD under a range of assumed scenarios.  The scenarios 
under consideration are summarized below in Table 4.  The scenarios describe the full range of 
possibilities: 
• 
Scenario 1 considers the case where all doses are safe (i.e., true toxicity probability is 
below the target threshold for each dose. 
• 
Scenarios 2-5 consider the case where the true target toxicity level of 10% occurs at each 
successive dose level under consideration. 
• 
Scenario 6 considers the case where no dose level is safe (i.e., true toxicity probably is 
above the target threshold for all doses. 
Table 4. Assumed True Toxicity Probabilities for Simulation Scenarios 
Scenario 
Description 
Dose Level 
120 
240 
360 
540 
1 
MTD = Dose 4 
0.05 
0.05 
0.05 
0.05 
2 
MTD = Dose 4 
0.05 
0.05 
0.07 
0.10 
3 
MTD = Dose 3 
0.05 
0.07 
0.10 
0.15 
4 
MTD = Dose 2 
0.05 
0.10 
0.15 
0.20 
5 
MTD = Dose 1 
0.10 
0.15 
0.20 
0.25 
6 
No MTD 
0.15 
0.20 
0.25 
0.30 
 
The results of the simulation study are summarized in table 5, and contrasted to the results from a 
pure 3+3 design (which was proposed in the original version of the protocol).  Below, we provide a 
short summary of the findings from the simulation study: 
• 
In scenario 1, both CRM approaches and the 3+3 method select the highest dose with high 
probability. 
• 
In scenarios 2-5, both CRM approaches generally do a better job at selecting the “correct” 
dose as the MTD.  The 3+3 method does slightly better at selecting the highest dose when 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 64 of 81 
it is the MTD (scenario 2).  However, this comes at a cost of “overshooting” the MTD when 
the true MTD occurs at a lower dose – as high as 88% under scenario 5. 
• 
In scenario 6, the CRM approaches correctly conclude that no dose satisfies the criteria of 
MTD over half of the time, whereas the 3+3 has a small probability of declaring no MTD 
and seems to select any of the four doses in a near uniform manner. 
 
Table 5. Results of Simulation Study 
Scenario 
Dose 
Level 
% Recommended 
# Subjects Allocated 
%True 
Toxicity  
CRM 
 
 
CRM 
CRMlag 
3+3 
CRM 
CRMlag 
3+3 
 
1 
None 
0% 
1% 
1% 
 
 
 
 
 
120 
2% 
2% 
2% 
8.1 
11.5 
3.5 
5% 
 
240 
3% 
4% 
2% 
5.3 
8.9 
3.4 
5% 
 
360 
4% 
5% 
3% 
5.4 
8.0 
3.6 
5% 
 
540 
91% 
88% 
91% 
42.2 
32.6 
45.2 
5% 
2 
None 
1% 
1% 
1% 
 
 
 
 
 
120 
4% 
4% 
2% 
9.3 
12.4 
3.4 
5% 
 
240 
9% 
9% 
2% 
8.3 
10.8 
3.4 
5% 
 
360 
19% 
19% 
10% 
10.4 
11.4 
4.4 
7% 
 
540 
68% 
67% 
86% 
36.8 
29.7 
33.8 
10% 
3 
None 
1% 
1% 
1% 
 
 
 
 
 
120 
10% 
10% 
2% 
13.8 
15.7 
3.5 
5% 
 
240 
25% 
25% 
4% 
14.0 
14.9 
3.6 
7% 
 
360 
32% 
31% 
19% 
14.2 
13.9 
5.0 
10% 
 
540 
32% 
33% 
74% 
23.6 
20.9 
23.1 
15% 
4 
None 
1% 
2% 
1% 
 
 
 
 
 
120 
27% 
26% 
2% 
22.0 
22.5 
3.5 
5% 
 
240 
42% 
42% 
8% 
19.1 
19.3 
4.1 
10% 
 
360 
21% 
21% 
29% 
12.4 
12.6 
5.6 
15% 
 
540 
9% 
10% 
59% 
12.1 
11.1 
15.5 
20% 
5 
None 
21% 
20% 
3% 
 
 
 
 
 
120 
54% 
54% 
9% 
37.4 
36.9 
4.0 
10% 
 
240 
20% 
20% 
16% 
12.5 
13.9 
4.4 
15% 
 
360 
5% 
5% 
32% 
6.1 
6.4 
5.2 
20% 
 
540 
1% 
1% 
41% 
4.8 
3.8 
9.4 
25% 
6 
None 
61% 
61% 
6% 
 
 
 
 
 
120 
34% 
34% 
19% 
39.4 
39.0 
4.5 
15% 
 
240 
4% 
4% 
22% 
6.2 
7.7 
4.5 
20% 
 
360 
1% 
1% 
29% 
2.8 
2.7 
4.4 
25% 
 
540 
0% 
0% 
24% 
1.9 
1.3 
5.2 
30% 
 
In summary, both modified CRM approaches generally have better performance with respect to 
successfully recommending the correct dose as the MTD (based on prior assumptions), and are 
well suited to achieve the goals of this study.  The modified CRM being used here performs no 
better than the more traditional approach at identifying the true MTD when it occurs at one of the 
intermediate doses.  Clearly, better accuracy could be achieved by increasing the sample size for 
the study.  However, when weighed against the costs of a larger study, the proposed sample size 
provides the right balance with respect to selecting the correct dose across all scenarios, and 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 65 of 81 
considering the probabilities of both ‘undershooting’ and ‘overshooting’ the assumed true MTD.  
Some efficiency is sacrificed by using the lagged version of the modified CRM.  However, this minor 
loss of efficiency is completely offset by the operational advantages of requiring fewer “extra 
placebo subjects” be enrolled. 
 
8.3.2 
Secondary Outcome (Bleed Rates) 
We also assessed the power of the study to evaluate bleed rates between all treated subjects 
(collapsed across doses) versus placebo subjects.  Previous experience suggests that the MRI-
detected bleed rate for tPA-treated subjects should be approximately 30%-40%56-62. Furthermore, 
it is expected from pre-clinical studies that treatment with APC could lead to a rather dramatic 
decrease in bleed rates for 3K3A-treated subjects31,44,63. Pre-clinical data suggest that 3K3A-APC 
could reduce bleeding seen after IV tPA or after mechanical thrombectomy44,63. Thus, it is expected 
that the study could observe a difference between the groups as substantial as a reduction from a 
40% bleed rate among placebo subjects to a lack of observed bleeding in the treated group.  
However, to assess power over a range of conditions, we computed power for all combinations of 
the following conditions: 
• 
Placebo group bleed rates of 20%, 30%, & 40% 
• 
3K3A-APC treated group bleed rates of 0.5%, 5%, & 10% 
• 
Overall sample sizes of 48 (36 treated / 12 control) and 88 (66 treated / 22 control) – in 
order to assess power under the scenario where the trial proceeds to the end and under 
the scenario where the study stops early for lack of observing any toxicity at the highest 
dose 
Table 6 provides a summary of these power calculations.  In general, we find: 
• 
If the original assumptions are correct: 
We would have very high power (>90%) in either scenario 
• 
If the original assumption regarding the placebo rate is correct, but the treated rate is a bit 
higher: 
We would have very good power (>85%) if the study proceeds to the end.  We would 
have lower, but a still acceptable level of power (>64%) if the study stops due to a lack of 
observed toxicity after 12 cohorts. 
• 
If the original assumption regarding the treatment rate is correct, but the placebo rate is a 
bit lower: 
We would have decent power (>66%) in either scenario, and very good power (>84%) in 
the scenario where the study proceeds to the end. 
• 
If both assumptions are wrong (placebo rate lower, treatment rate higher): 
There is lower power overall, but still reasonable power in a number of settings (such as 
30% placebo rate versus 10% treated rate) 
In conclusion, it appears that the study has adequate power to detect differences in bleeding of 
interest, even if our assumptions are slightly optimistic.  We believe that this sufficiently supports 
the adequacy of the comparison of bleeding rates.  

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 66 of 81 
Table 6. Power for Comparing Bleed Rates (Assumes Chi-Square Test, Significance Level 
= 0.05, and 75% of Subjects Assigned to Treatment) 
Assumed Bleed Rate 
in Treated Group 
Assumed Bleed Rate in Placebo Group 
20% 
30% 
40% 
N = 48 
N = 88 
N = 48 
N = 88 
N = 48 
N = 88 
0.5% 
66% 
84% 
82% 
95% 
92% 
99% 
5% 
39% 
56% 
63% 
83% 
80% 
96% 
10% 
18% 
26% 
41% 
61% 
64% 
85% 
 
8.4 
Data Monitoring 
All aspects of the study will be monitored by qualified individuals designated by the sponsor.  
Monitoring will be conducted according to Good Clinical Practice and applicable government 
regulations.  The Investigator agrees to provide monitors access to the clinical supplies, dispensing 
and storage areas, and to the clinical files of the study subjects, and, if requested, agrees to assist 
the monitors. The site will provide the monitor adequate working space and full access to the 
medical record. If the site uses an electronic medical record, the monitor will be provided a 
temporary password and access to one patient chart, or, the site coordinator will be available 
throughout the monitoring visit to provide access. The site PI will be available for an exit visit with 
the monitor. 
Safety monitoring will include careful assessment and appropriate reporting of adverse events.  
Medical monitoring will include contemporaneous assessment of serious adverse events. 
The monitoring of subject safety and data quality will follow the NINDS Guidelines for Data and 
Safety Monitoring in Clinical Trials.  A Data and Safety Monitoring Board (DSMB) appointed by the 
NIH/NINDS will meet at approximately six-month intervals (or as determined by the NINDS) to 
review partially unblinded study data provided by the study statistician.  This committee will monitor 
rates of adverse events and endpoints in the trial and will monitor the performance of the trial. The 
frequency and format of DSMB meetings, reports, and guidelines for interim analysis will be agreed 
upon prior to study subject enrollment during the first meeting of the DSMB with the representatives 
of the DCC. The DSMB will review the data seen by the SRC during their deliberations of dose 
escalation steps. 
The Protocol PI will appoint an Independent Medical Monitor (IMM) to review all adverse events in 
a blinded real-time fashion in order to monitor for AEs that could meet the definition of a DLT. 
Should a DLT be reported or suspected, the IMM will notify the SRC, which will be convened to 
review the AE(s). In addition, the IMM will review all events that meet the regulatory definition of a 
Serious Adverse Event, upon receipt of notification via the Electronic Data Capture (EDC).    
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in 
humans whether or not considered drug related.  FDA, Office of Human Research Protection 
(OHRP), and NeuroNEXT CIRB requirements for reporting AEs will be followed. Subjects who 
receive investigational treatment will be monitored for AEs from the time they sign consent until 7 
days for AEs and 30 days for SAEs following permanent discontinuation of study drug. At that point, 
all ongoing AEs will be followed to resolution, or until Day 90, but no new AEs will be recorded. The 
IMM/DSMB will review cumulative AEs; the frequency of this review will be determined by the 
IMM/DSMB in conjunction with the Protocol PI. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 67 of 81 
Each Clinical Study Site Principal Investigator (CSS PI) and research team (co-Investigators, 
research nurse, clinical trial coordinator) are responsible for identifying and reporting AEs.  The 
CSS PI is responsible for determining the relationship of the event to the study drug/study 
procedures.  Aggregate reports blinded by treatment group, detailed by severity, attribution 
(expected or unexpected), and relationship to the study drug/study procedures, will be available 
from the DCC for review by the IMM. A separate report detailing protocol compliance will also be 
available monthly from the DCC for review by the Protocol PI, who will provide feedback to 
individual sites as needed. The Protocol Steering Committee (PSC) will advise the Protocol PI as 
to whether the protocol or informed consent document requires revision based on these reports.  
8.5 
Data Analyses 
8.5.1 
Primary Objective 
Determine Maximum Tolerated Dose: The MTD will be selected using the rules specified above 
for the implementation of the CRM model.  The MTD will be defined as the dose that would be 
chosen from the CRM model at the final step.  Additional safety assessments will compare the 
groups on the basis of all AEs, changes in laboratory and vital signs values, and results of physical 
examinations.  AEs will be classified with regard to seriousness, severity, duration, and relatedness 
of the event.  AE data will be listed individually and will be descriptively summarized by body 
system, preferred terms within a body system, and treatment dose. 
8.5.2 
Secondary Objectives 
Secondary Outcome #1 (PK Parameters):  Based upon analysis of PK data from the Phase I 
study, a one-compartment IV infusion model will be used and will be parameterized in terms of the 
primary parameters clearance (CL) and volume of distribution (V).  Secondary parameters will 
include Cmax, AUC0-inf, and t1/2 – and will be calculated from the primary parameters.  The actual 
times of the beginning and end of all 5 infusions and each blood sampling time relative to the first 
dose will be used in the modeling.  All modeling will be done using WinNonlin. 
Secondary Outcome #2 (Bleed Rates): To assess tPA/mechanical thrombectomy-related bleed 
rates across the two groups, all treated subjects (regardless of dose) will be compared to all placebo 
subjects using a Pearson chi-square test.  An additional analysis will compare the bleed rates 
among placebo subjects and subjects treated at each dose level (assuming a sufficient number of 
subjects were treated at that level). 
Exploratory Outcomes: (Stroke Outcome and Immunogenicity Data): To inform the design of 
any future Phase III trial, the following exploratory outcomes will be compared at the end of the 
study.  Unless explicitly stated otherwise, the comparisons will be conducted first comparing all 
treated subjects (regardless of dose) versus all placebo subjects, and then comparing all subjects 
receiving the dose selected as the MTD versus all placebo subjects. 
• 
The mean bleeding (hemorrhage and microbleeds) volume at Day 30 will be compared 
using a linear regression model.  Median and categorical volumes (based upon quartiles) 
will be compared. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 68 of 81 
• 
Rates of subarachnoid hemorrhage in subjects who receive mechanical thrombectomy will 
be compared; all mechanical thrombectomy 3K3A-APC-treated subjects (regardless of 
dose) will be compared to all placebo subjects using a Pearson chi-square test. 
• 
The 7-day NIHSS mean scores will be compared using a Kruskal-Wallis test. 
• 
The change from Baseline NIHSS to 7-day NIHSS will be compared using a linear 
regression model, with baseline NIHSS score as a covariate. 
• 
The 90-day mRS will be compared using a Pearson chi-square test. 
• 
The mean infarct volume at 90 days (MRI, or CT if unable to obtain MRI) will be compared 
using a linear regression model.  Median and categorical infarct volumes (based upon 
quartiles) will be compared. 
• 
The 90-day BI will be compared using a Kruskal-Wallis test. 
• 
The relationship between the 7-day NIHSS score and the 90-day mRS will be examined 
using a linear regression model.  The degree of fit and the R-square will be determined, 
and the model will be used to assess the potential for using the 7-day outcome in 
subsequent studies. 
• 
The tendency of the drug to induce an immunogenic response in patients will be assessed. 
 
9 
DATA COLLECTION, SITE MONITORING, AND ADVERSE EXPERIENCE REPORTING 
9.1 
Data Management 
Site personnel will collect, transcribe, correct, and transmit the data onto source documents, CRFs, 
and other forms used to report, track and record clinical research data.  The DCC will monitor 
clinical sites to ensure compliance with data management requirements and Good Clinical 
Practices. The DCC is responsible for developing, testing, and managing clinical data management 
activities, as required, at the study sites, the CCC, and at the DCC. 
The general NINDS Common Data Elements (CDE) will be used to construct data collection forms. 
All study data will be collected via systems created in collaboration with the DCC and will comply 
with all applicable guidelines regarding patient confidentiality and data integrity. 
9.1.1 
Enrollment Registration  
Participants will be considered screened after signing the informed consent form for this study.  
Eligible screened participants will be ‘randomized’ once registered in the NeuroNEXT IWRS and 
considered ‘dosed’ only after receipt of study drug. Enrollment of participants on this protocol will 
employ an interactive data system in which the clinical study site will attest to the participant’s 
eligibility as per protocol criteria after obtaining informed consent. NeuroNEXT CIRB approval for 
the protocol must be on file at the DCC before accrual can occur from the clinical study site. The 
participant is not considered validly enrolled until the first study infusion begins. If a participant 
becomes ineligible between randomization and the onset of study drug infusion, he/she will be 
considered a randomization failure and will be replaced.   

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 69 of 81 
The DCC will use a system of coded identifiers to protect participant confidentiality.  When the 
participant is registered to participate in the study using the DCC-provided web-based registration, 
the system will assign a participant ID number. The unique ID code will include a protocol ID, a site 
ID, and a unique participant ID.  To confirm the correct participant ID, the data entry system will 
require a second entry of the unique participant ID and compare for consistency.  In this fashion, 
no personal identifiers would be accessible to the DCC and the data will be collected on the 
correctly identified subject.  
9.1.2 
Data Entry 
Data entry will occur at the enrolling clinical study sites. Data quality assurance and analyses will 
be performed by the DCC.  The DCC, located at The University of Iowa, will coordinate all data and 
statistical services for the study, as well as on-site monitoring for all participating clinical study sites. 
Data collection for this study will be accomplished with online electronic case report forms.  Using 
encrypted communication links, online forms will be developed that contain the requisite data 
fields.   
9.2 
Role of Data Management 
Data Management (DM) is the development, execution and supervision of plans, policies, 
programs, and practices that control, protect, deliver, and enhance the value of data and 
information assets. 
All data will be managed in compliance with NeuroNEXT policies, and applicable Sponsor and 
regulatory requirements. The DCC will instruct site personnel to collect, transcribe, correct, and 
transmit the data onto source documents, CRFs, and other forms used to report, track and record 
clinical research data.  The DCC will monitor clinical sites to ensure compliance with data 
management requirements and Good Clinical Practices. The DCC is responsible for developing, 
testing, and managing clinical data management activities, as required, at the clinical study sites 
(CSS), the CCC, and at the DCC. 
The DCC is responsible for all aspects of clinical data management, and for properly instructing 
key study personnel (including the CCC, the CSS, and DCC staff) on how to collect, transcribe, 
correct and transmit the data onto CRFs or other data collection forms and logs. 
The DCC is responsible for establishing procedures to ensure that clinical data management 
activities occur as required at the CCC, the CSS, and at the DCC. 
9.3 
Quality Assurance 
By signing this protocol, the Sponsor and Investigator agree to be responsible for implementing 
and maintaining quality control and quality assurance systems with written standard operating 
procedures (SOPs) to ensure that studies are conducted and data are generated, documented, 
and reported in compliance with the protocol, accepted standards of GCP, and all applicable 
federal, state, and local laws, rules and regulations relating to the conduct of the clinical study. 
All participating clinical sites have been pre-qualified by the NeuroNEXT management team 
according to NeuroNEXT SOPs. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 70 of 81 
9.3.1 
Development of Monitoring Plan 
On-site monitoring visits will be conducted by DCC monitors according to a pre-defined Monitoring 
Plan.  The Monitoring Plan will detail the frequency of on-site visits, the study data to be monitored, 
the review of any regulatory files, drug and supplies accountability (if applicable), documentation of 
the on-site visit, and the resolution process for data errors that are discovered during the visits.   All 
participating clinical study sites will be monitored at least once after study initiation and all sites will 
have a close-out visit for each protocol.  One on-site blinded monitoring visit is anticipated for each 
clinical study site per year. Additionally, one on-site unblinded pharmacy visit is anticipated for each 
site per year.  All subjects will be monitored for inclusion and exclusion criteria, informed consent 
procedures, and adverse events.  A certain percentage of data is also monitored/ source data 
verified against the data entered into the study database.  The monitoring plan will include flexibility 
to revise the frequency of visits or data monitored depending on clinical study site or study related 
issues. 
9.3.2 
Site Monitoring Visits 
On-site blinded monitoring visits will be conducted by DCC monitors according to a pre-defined 
Monitoring Plan for each protocol. The goal of on-site monitoring is to analyze (review) the data as 
it is collected, to check the validity and integrity of the data, to verify source documentation, to 
ensure protection of human subjects, and to ensure protocol compliance with federal regulations.  
During the monitoring visit, the monitor assesses the overall status of the study, staff, and facilities 
to determine whether the study is being conducted per protocol and in compliance with regulatory 
requirements.  The monitor also conducts a CRF review that includes checks of all adverse event 
documentation, verifies the presence of all critical correspondence and records related to 
investigational products and clinical supplies (if applicable), and determines if protocol violations 
have occurred and are documented properly.  After the monitoring visit, the monitor documents the 
results of the monitoring visit and completes a post-visit monitoring letter that conveys any issues 
discovered during the visit and the need for data corrections, if appropriate.  Unblinded pharmacy 
monitoring visits will be conducted by independent monitors to ensure proper drug storage, 
handling and administration. Drug and supplies accountability may also be monitored during the 
site visit.  The DCC will work closely with the unblinded pharmacy monitors to monitor and 
document drug distribution from the manufacturers to the clinical study sites (CSS).  Each CSS will 
be provided with a drug accountability log, which will be reviewed by the independent monitors and 
reconciled with distribution logs.   At the study closeout visit, the monitors confirm that appropriate 
data have been reviewed, source documentation has been verified, and all required documents are 
present in the Study Regulatory File. 
9.3.3 
Laboratory Data Flow 
Safety Monitoring Labs: The DCC will provide clinical study sites with online forms and/or electronic 
data exchange mechanisms, depending on their capabilities and needs, in order to enter, update, 
and obtain relevant data.  The CSS will be responsible for the entry of laboratory data into the 
electronic data capture (EDC) system. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 71 of 81 
9.4 
Adverse Experience Reporting 
The adverse event (AE) definitions and reporting procedures provided in this protocol comply with 
all applicable United States Food and Drug Administration (FDA) regulations and International 
Conference on Harmonization (ICH) guidelines.  The Site Investigator will carefully monitor each 
subject throughout the study for possible adverse events.  All AEs will be documented on CRFs 
designed specifically for this purpose.  It is important to report all AEs, especially those that result 
in permanent discontinuation of the investigational product being studied, whether serious or non-
serious. 
AEs should be collected and reported on subjects who receive investigational treatment from 
signing of the ICF through study Day 7, and should be followed until resolution or a new baseline 
is established, but no longer than study Day 90. Any AEs that occur prior to informed consent 
should be included in the subject’s medical history. SAEs will be collected and reported on subjects 
who receive investigational treatment from signing of the ICF through study Day 30, and should be 
followed until resolution (or resolution with sequelae), but no longer than study Day 90.  
Each clinical study site’s Principal Investigator and research team are responsible for identifying 
adverse events and reporting them through the DCC Online Adverse Event Reporting System.  
Investigators are also responsible for complying with NeuroNEXT CIRB’s reporting requirements 
for all safety reports.  Copies of each report and documentation of IRB notification and receipt will 
be kept in the Investigator’s study file. 
Headache has been identified as an AE that we would like to further characterize.  Therefore, all 
headaches that start after signing of the ICF should be documented as AEs, and Investigators 
should also complete the Headache Record CRF.  A new AE form and new Headache Record 
should be completed for each new headache during the first seven days. Headaches that start prior 
to signing of the ICF and do not worsen should be reported only on the Medical History CRF and 
the Headache Record CRF should not be completed. If however, a headache begins prior to 
consent and later worsens it should be reported as an AE and the Headache Record CRF should 
be completed. 
On-line Adverse Event Reporting System  
Upon entry of a serious adverse event by a site Investigator, the DCC Online Adverse Event 
Reporting System will immediately notify the Independent Medical Monitor (IMM).   
• Within 24 hours (of learning of the event), Investigators must report any Serious Adverse Event 
(SAE). Investigators should report all other AEs within 5 working days/7 calendar days (of 
learning of the event). 
Serious adverse events: The site Investigator determines causality (definitely not related, unlikely 
related, possibly related, probably related, definitely related) of the adverse event. The IMM will 
review the SAE report.  The IMM may request further information if necessary.  The Online Adverse 
Event Reporting System maintains audit trails and stores data (and data updated) and 
communication related to any adverse event in the study.  The Sponsor in conjunction with the IMM 
may determine that the Serious Adverse Event requires expedited reporting to the FDA.  The DCC 
will prepare a MedWatch safety report for submission to the FDA.  If warranted, the IMM will notify 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 72 of 81 
the DSMB chair.  The DSMB may suggest changes to the protocol or consent form to the Study 
Chair as a consequence of adverse events.  
Non-serious adverse events: Non-serious adverse events that are reported to or observed by the 
Investigator or a member of his/her research team should be submitted to the DCC in a timely 
fashion (within 5 working days/7 calendar days). See the ‘Site Manual of Operations’ for more 
detail. The events will be presented in tabular form and given to the IMM on a quarterly basis or as 
requested. Local site Investigators are also required to fulfill all reporting requirements of their local 
institutions. 
The DCC will prepare aggregate reports of all adverse events (serious/not serious, 
expected/unexpected and relationship to study drug) for the IMM and the DSMB on a quarterly 
basis or as requested. In addition, all adverse events will be coded using the MedDRA system. A 
separate report detailing protocol compliance will also be available from the DCC for DSMB and/or 
site review monthly or as requested. The research team will then evaluate whether the protocol or 
informed consent document requires revision based on the reports.  
9.4.1 
Definitions of Adverse Events, Suspected Adverse Drug Reactions & Serious 
Adverse Events 
9.4.1.1 Adverse Event and Suspected Adverse Drug Reactions 
An adverse event (AE) is any untoward occurrence associated with the use of a drug in humans 
whether or not considered drug related. 
A pretreatment AE is any untoward medical occurrence that occurs after consent signed and prior 
to study drug administration.  
Adverse drug reactions (ADR) are all noxious and unintended responses to a medicinal product 
related to any dose.  The phrase “responses to a medicinal product” means that a causal 
relationship between a medicinal product and an adverse event is at least a reasonable possibility, 
i.e., the relationship cannot be ruled out.  Therefore, a subset of AEs can be classified as suspected 
ADRs, if there is a causal relationship to the medicinal product. 
Examples of adverse events include: new conditions, worsening of pre-existing conditions, clinically 
significant abnormal physical examination signs (i.e. skin rash, peripheral edema, etc.), or clinically 
significant abnormal test results (i.e. lab values or vital signs), with the exception of outcome 
measure results, which are not being recorded as adverse events in this trial (they are being 
collected, but analyzed separately). Stable chronic conditions (i.e., diabetes, arthritis) that are 
present prior to the start of the study and do not worsen during the trial are NOT considered adverse 
events. Chronic conditions that occur more frequently (for intermittent conditions) or with greater 
severity, would be considered as worsened and therefore would be recorded as adverse events. 
Adverse events are generally detected in two ways: 
 
Clinical → symptoms reported by the subject or signs detected on examination. 
Ancillary Tests → abnormalities of vital signs, laboratory tests, and other diagnostic procedures 
(other than the outcome measures: the results of which are not being captured as AEs). 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 73 of 81 
If discernible at the time of completing the AE source documentation, a specific disease or 
syndrome rather than individual associated signs and symptoms should be identified by the Site 
Investigator and recorded in the AE source documentation.  However, if an observed or reported 
sign, symptom, or clinically significant laboratory anomaly is not considered by the Site Investigator 
to be a component of a specific disease or syndrome, then it should be recorded as a separate AE 
in the source documentation.  Clinically significant laboratory abnormalities, such as those that 
require intervention, are those that are identified as such by the Site Investigator. 
An unexpected adverse event is any adverse event, the specificity or severity of which is not 
consistent with the current Investigators Brochure or package insert or described in the protocol.  
An unexpected, suspected adverse drug reaction is any unexpected adverse event that, in the 
opinion of the Site Investigator or Sponsor, there is a reasonable possibility that the investigational 
product caused the event. 
9.4.1.2 Serious Adverse Events 
A serious adverse event (SAE) is defined as an adverse event that meets any of the following 
criteria: 
1. Results in death. 
2. Is life threatening: that is, poses an immediate risk of death as the event occurred. 
a. This serious criterion applies if the study subject, in the view of the Site Investigator or 
Sponsor, is at immediate risk of death from the AE as it occurs.  It does not apply if an 
AE hypothetically might have caused death if it were more severe. 
3. Requires inpatient hospitalization or prolongation of existing hospitalization. 
a. Hospitalization for an elective procedure (including elective PEG tube/g-tube/feeding 
tube placement) or a routinely scheduled treatment is not an SAE by this criterion 
because an elective or scheduled “procedure” or a “treatment” is not an untoward 
medical occurrence. 
4. Results in persistent or significant disability or incapacity. 
a. This serious criterion applies if the “disability” caused by the reported AE results in a 
substantial disruption of the subject’s ability to carry out normal life functions. 
5. Results in congenital anomaly or birth defect in the offspring of the subject (whether the subject 
is male or female).   
6. Necessitates medical or surgical intervention to preclude permanent impairment of a body 
function or permanent damage to a body structure. 
7. Important medical events that may not result in death, are not life-threatening, or do not require 
hospitalization may also be considered SAEs when, based upon appropriate medical judgment, 
may jeopardize the subject and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition.  Examples of such medical events include blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of 
drug dependency or drug abuse. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 74 of 81 
An inpatient hospital admission in the absence of a precipitating, treatment-emergent, clinical 
adverse event may meet criteria for "seriousness" but is not an adverse experience, and will 
therefore, not be considered an SAE.  An example of this would include a social admission (subject 
admitted for other reasons than medical, e.g., lives far from the hospital, has no place to sleep). 
A serious, suspected adverse drug reaction is an SAE that, in the opinion of the Site Investigator 
or Sponsor, suggests a reasonable possibility that the investigational product caused the event. 
The Site Investigator is responsible for classifying adverse events as serious or non-serious. 
9.4.1.3 Neuroworsening 
For the purposes of this protocol neurologic worsening is defined as a 4 or more points increase 
on the NIHSS, as compared to the most recent NIHSS, that lasts for more than 8 hours, is confirmed 
by a repeat NIHSS, follows administration of study drug, is resulting from edema, hemorrhage, 
hydrocephalus and/or extending infarct and is not felt to be attributable to non-neurologic causes, 
such as iatrogenic sedation or medical co-morbidities. The cause of the neuroworsening will be 
captured as a serious adverse event and, if occurring during the DLT reporting period, will be 
evaluated by the IMM as a potential DLT.  For each case, sufficient imaging will be selected by the 
CSS Investigator, de-identified and submitted to the IMM for review so that he can confirm the 
reason for neuroworsening. Refer to the ‘Imaging Plan’ for details. The Investigator will be asked 
to give the primary and contributing causes of the worsening, and to gauge the depth of worsening 
by performing a NIHSS as close to the nadir as possible.  The IMM will review all cases of 
neuroworsening and will refer suspected cases of SICH to the SRC for adjudication; refer to the 
‘Safety Management Plan’ for details. 
If a subject’s neurological status deteriorates (whether gradually or rapidly) once the DLT 
observation period has expired the event will be reported as an AE/SAE as applicable but will not 
be considered neuroworsening according to the definition listed above. 
9.4.1.4 Symptomatic Intracranial Hemorrhage (SICH) 
All patients will have a follow-up CT scan at 24-36 hours following the tPA bolus, per local SOC 
and as deemed necessary by the investigator. If a CSS uses MRI as SOC at this time point, it is 
encouraged that the MRI protocol for this study be used. Symptomatic intracranial hemorrhage is 
defined as blood present on CT or MRI brain images that is associated with clinical worsening that 
meets the definition of neuroworsening (4 or more point increase in NIHSS; see section 9.4.1.3 for 
definition) and in the opinion of the Investigator represents a clinically significant change that can 
be attributed to the hemorrhage3. For each case, sufficient imaging will be selected by the CSS 
Investigator, de-identified and submitted to the IMM and SRC for review so that the SRC can 
adjudicate the possible DLT; refer to the ‘Imaging Plan’ and ‘Safety Management Plan’ for details. 
9.4.1.5 Assessment and Recording of Adverse Events 
This study will utilize the CTCAE version 4.03 coding system for adverse event recording.  Adverse 
events reported using CTCAE will be recoded into MedDRA terms by the DCC. 
Assessment of Adverse Events 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 75 of 81 
At each visit (including telephone interviews), the subject will be asked “Have you had any problems 
or symptoms since your last visit?” in order to determine the occurrence of adverse events. If the 
subject reports an adverse event, the Investigator will determine: 
 
1. Type of event 
2. Date of onset and resolution (duration) 
3. Severity (mild, moderate, severe, life-threatening, results in death) 
4. Seriousness (does the event meet the above definition for an SAE) 
5. Causality, relation to investigational product and disease 
6. Action taken regarding investigational product 
7. Outcome 
 
Severity of Adverse Events  
The severity of AEs and SAEs will be graded according to CTCAE, version 4.03.  Any AE not listed 
in the CTCAE will be graded as follows: 
Grade 1:  Mild - Transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required.  
Grade 2:  Moderate - Mild to moderate limitation in activity; some assistance may be 
needed; no or minimal medical intervention/therapy required.  
Grade 3:  Severe - Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required; hospitalizations possible.  
Grade 4: Potentially Life-Threatening - Extreme limitation in activity; significant assistance 
required; significant medical intervention/therapy required; hospitalization or hospice care 
probable. 
Grade 5: Death – The AE results in death. 
Relatedness of Adverse Event to Investigational Product 
The relationship of the AE to the investigational product should be specified by the Site Investigator, 
using the following definitions: 
 
1. Not Related: Concomitant illness, accident or event with no reasonable association with 
treatment. 
2. Unlikely: The reaction has little or no temporal sequence from administration of the 
investigational product, and/or a more likely alternative etiology exists. 
3. Possibly Related: The reaction follows a reasonably temporal sequence from administration of 
the investigational product and follows a known response pattern to the suspected 
investigational product; the reaction could have been produced by the investigational product or 
could have been produced by the subject’s clinical state or by other modes of therapy 
administered to the subject. (suspected ADR) 
4. Probably Related: 
The reaction follows a reasonably temporal sequence from administration 
of investigational product; is confirmed by discontinuation of the investigational product or by re-
challenge; and cannot be reasonably explained by the known characteristics of the subject’s 
clinical state. (suspected ADR) 
5. Definitely Related: 
The reaction follows a reasonable temporal sequence from administration 
of investigational product; that follows a known or expected response pattern to the 
investigational product; and that is confirmed by improvement on stopping or reducing the 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 76 of 81 
dosage of the investigational product, and reappearance of the reaction on repeated exposure 
(suspected ADR). 
Recording of Adverse Events 
All clinical adverse events are recorded in the Adverse Event (AE) data entry template in the 
subject’s study binder. The site should fill out the AE data entry template and enter the AE 
information into the online Adverse Event Reporting System within 5 working days/7 calendar days 
of the site learning of a new AE or receiving an update on an existing AE.   
Please Note: Serious Adverse Events (SAEs) must be reported to the NeuroNEXT Data 
Coordinating Center within 24 hours of the site learning of the SAE.  
Entries in the AE data entry template (and into the online Adverse Event Reporting System) will 
include the following: name and severity of the event, the date of onset, the date of resolution, 
relationship to investigational product, action taken, and primary outcome of event. 
Adverse Events and Serious Adverse Events - Reportable Events 
The following are considered reportable events and must be reported to the NeuroNEXT Data 
Coordinating Center within 24 hours of the site being notified of the event.  
• 
All events that meet the above criteria for Serious Adverse Events (SAEs) 
All occurrences of Serious Adverse Events (SAEs) must be reported within 24 hours of discovery 
of the event.   All other Adverse Events (AEs) should be reported within 5 working days/7 calendar 
days (of discovery of the event). 
Adverse Event Data Management System (AEDAMS) 
Upon entry of a serious adverse event by a clinical site, the DCC Online Adverse Event Reporting 
System will immediately notify the IMM. If warranted, the IMM will notify the DSMB chair.  
Serious adverse events: The site Investigator determines causality (definitely not related, probably 
not related, possibly related, probably related, definitely related) of the adverse event. The IMM will 
review the SAE report.  The IMM may request further information if necessary.  The DSMB may 
suggest changes to the protocol or consent form to the Project PI as a consequence of adverse 
events. The Online Adverse Event Reporting System maintains audit trails and stores data (and 
data updated) and communication related to any adverse event in the study.  
Non-serious adverse events: Non-serious adverse events that are reported to or observed by the 
Investigator or a member of his/her research team should be submitted to the DCC within 5 working 
days/7 calendar days. The events will be presented by DCC in tabular form and given to the IMM 
on a monthly basis or as requested. Local site Investigators are also required to fulfill all reporting 
requirements of their local institutions. 
The DCC will prepare aggregate reports of all adverse events (serious/not serious and expected, 
unexpected) for the DSMB.  
9.4.1.6 Breaking the Study Blind  
Every effort should be made to preserve the double-blind treatment assignment of study subjects 
in the randomized phase of the study. In the majority of cases, the Investigator should simply 
assume the patient is on active treatment and treat accordingly. Should EMERGENCY unblinding 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 77 of 81 
need to occur, the clinical staff (or pharmacist) must contact the NN104 study Hotline for 
permission.  
 
Hotline (24/7): 
 
The DCC will be immediately notified of the broken blind.  Refer to the ‘Site Manual of Operations’ 
for details. 
10 HUMAN SUBJECTS 
Documented approval from the NeuroNEXT CIRB will be obtained for all participating centers prior 
to clinical trial start, according to ICH GCP, local laws, regulations and organization. When 
necessary, an extension, amendment or renewal of the CIRB approval must be obtained. 
Evidence of training in responsible conduct of research shall be on file for each CSS PI and co-
Investigator. 
10.1 Central Institutional Review Board (CIRB) Review and Informed Consent 
This protocol and the informed consent document and any subsequent modifications will be 
reviewed and approved by the NeuroNEXT CIRB responsible for oversight of the study.  A signed 
consent form, approved by the NeuroNEXT CIRB, will be obtained from the subject.  For subjects 
who cannot provide consent for themselves, an authorized representative defined by the local 
regulations must sign the consent form; additionally, the subject's assent must also be obtained if 
he or she is able to understand the nature, significance, and risks associated with the study.  The 
consent form will describe the purpose of the study, the procedures to be followed, and the risks 
and benefits of participation.  A copy of the consent form will be given to the subject, and/or 
authorized representative, and this fact will be documented in the subject’s record. Should the 
subject regain capacity and consent was originally provided by someone else, the subject will be 
re-consented himself/herself. 
10.2 Subject Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records that leave the clinical study 
site will be identified only by the study specific Subject Identification Number (SID) to maintain 
subject confidentiality.  All records will be kept in a locked file cabinet.  All computer entry and 
networking programs will be done using study specific SIDs only.  Clinical information will not be 
released without written permission of the subject, except as necessary for monitoring by CIRB, 
the FDA, the NINDS, the OHRP, the Sponsor, or the Sponsor’s designee.  
10.3 Study Modification/Discontinuation 
The study may be modified or discontinued at any time by the CIRB, the NINDS, the sponsor, the 
OHRP, the FDA, or other government agencies as part of their duties to ensure that research 
subjects are protected. 
11 PUBLICATION OF RESEARCH FINDINGS 
Publication of the results of this trial will be governed by the policies of the NeuroNEXT Network 
and procedures developed by the NeuroNEXT Data Sharing and Publication Committee.  Any 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 78 of 81 
presentation, abstract, or manuscript will be made available for review by the Sponsor and the 
NINDS prior to submission. 
 
12 REFERENCES 
1. 
Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual 
reassessment method for phase I studies. Stat Med. June 15 1995;14(11):1149-1161. 
2. 
Hacke W, Kaste M, Bluhmki E, et al for the ECASS Investigators. Thrombolysis with 
Alteplase 3 to 4.5 Hoursafter Acute Ischemic Stroke. The New England Journal of 
Medicine. 2008;359(13):1317-1329. 
3. 
Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with 
alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in 
Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-
282. 
4. 
Goyal M, Demchuk AM, Menon BK et al. Randomized Assessment of Rapid 
Endovascular Treatment of Ischemic Stroke. N Engl J Med. 2015. 
5. 
Campbell BC, Mitchell PJ, Kleinig TJ et al. Endovascular Therapy for Ischemic Stroke 
with Perfusion-Imaging Selection. N Engl J Med. 
6. 
Berkhemer OA, Fransen PS, Beumer D et al. A randomized trial of intraarterial treatment 
for acute ischemic stroke. N Engl J Med. Jan 1 2015;372(1):11-20. 
7. 
Saver J, SOLITAIRE FR with the intention for thrombectomy as primary endovascular 
treatment for acute ischemic stroke. Feb 11 2015. 
8. 
Activase®(Alteplase) Prescribing Information. Genetech, Inc.; February 2015. 
9. 
Lloyd-Jones D, Adams RJ, Brown TM, et al, American Heart Association Statistics 
Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 
update: a report from the American Heart Association. Circulation. 2010;121(7):e46-
e215. 
10. 
American Heart Association. Heart Disease and Stroke Statistics – 2010 Update. Dallas: 
American Heart Association;2010. 
11. 
Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics--2006 update: 
a report from the American Heart Association Statistics Committee and Stroke Statistics 
Subcommittee. Circulation. 2006;113(6):e85-151. 
12. 
Stroke National Institute of Neurological Disorders and. Stroke: Hope Through Research. 
2010; http://www.ninds.nih.gov/disorders/stroke/detail_stroke.htm. 
13. 
Group NINDS rt-PA Stroke Study. Tissue plasminogen activator for acute ischemic 
stroke. N Engl J Med. 1995;333(24):1581-1587. 
14. 
Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients 
with acute ischemic stroke: a guideline for healthcare professionals from the American 
Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947. 
15. 
Stemer A, Lyden P. Evolution of the thrombolytic treatment window for acute ischemic 
stroke. Curr Neurol Neurosci Rep. January 2010;10(1):29-33. 
16. 
Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator 
therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 
2001;58(12):2009-2013. 
17. 
Kidwell CS, Jahan R, Alger JR. Design and rationale of the Mechanical Retrieval and 
Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial. Int J Stroke. 
2014;9(1):110-116. 
18. 
Ciccone A, Valvassori L, Nichelatti M. Endovascular treatment for acute ischemic stroke. 
N Engl J Med. 2013;368(10):904-913. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 79 of 81 
19. 
Broderick J,P Palesch YY, Demchuk AM. Endovascular therapy after intravenous t-PA 
versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893-903. 
20. 
Jovin TG, Chamorro A, Cobo E, de Miguel MA, et al. Thrombectomy within 8 hours after 
symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296-2306. 
21. 
Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with 
normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104(6):1740-1744. 
22. 
Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant 
activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis 
inhibitor-dependent cytoprotective functions. J Biol Chem. 2007;282(45):33022-33033. 
23. 
Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 
2007;109(8):3161-3172. 
24. 
Cheng T, Liu D, Griffin JH, Fernández JA, Castellino F, Rosen ED, Fukudome K, 
Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain 
endothelium and is neuroprotective. Nat Med. 2003;9(3):338-342. 
25. 
Dömötör E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV. Activated protein 
C alters cytosolic calcium flux in human brain endothelium via binding to endothelial 
protein C receptor and activation of protease activated receptor-1. Blood. 
2003;101(12):4797-4780. 
26. 
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of 
antithrombotic protein c defines new mechanisms modulating inflammation and 
apoptosis. J Biol Chem. 2001;276(14):11199-11203. 
27. 
Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells 
by activated protein C requires protease-activated receptor-1 and endothelial cell protein 
C receptor. Biochem J. 2003;373(Pt.1):65-70. 
28. 
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell 
protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-
1882. 
29. 
Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, Zlokovic BV. Tissue 
plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat 
Med. 2004;10:1379-1383. 
30. 
Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, Griffin JH, Zlokovic BV. 
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 
3. Neuron. 2004;41(4):563-572. 
31. 
Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, Liu D, Maggirwar SB, 
Deane R, Fernandez JA, LaRue B, Griffin JH, Chopp M, Zlokovic BV. Tissue 
plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat 
Med. 2006;12:278-285. 
32. 
Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV. Anti-
inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a 
murine model of focal ischemic stroke. Circulation. 2001;103:1799-1805. 
33. 
Zlokovic BV, Zhang C, Liu D, Fernandez J, Griffin JH, Chopp M. Functional recovery after 
embolic stroke in rodents by activated protein C. Ann Neurol. 2005;58(3):474-477. 
34. 
Thiyagarajan M, Fernandez JA, Lane SM, Griffin JH, Zlokovic BV. Activated protein C 
promotes neovascularization and neurogenesis in postischemic brain via protease-
activated receptor 1. J Neurosci. November 26 2008;28(48):12788-12797. 
35. 
Sutherland BA, Minnerup J, Balami JS, Arba F,, Buchan AM and Kleinschnitz C. 
Neuroprotection for ischaemic stroke: Translation from the bench to the bedside. Intern J 
Stroke. July 2012;7:407-418. 
36. 
Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke 
and neurological disorders. Trends Neurosci. 2011;34(4):198-209. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 80 of 81 
37. 
Fernández JA, Mosnier LO, Davis TP, Zlokovic BV and Griffin JH. Influence of the 3K3A-
activated protein C variant on the in vitro fibrinolytic activity of tPA J Thrombos 
Haemostas (submitted; acceptance pending). 
38. 
Xigris® Prescribing Information. Eli Lilly; 2008. 
39. 
Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human 
activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709. 
40. 
Activated Protein C in Acute Stroke Trial (APCAST). 2010; 
http://www.clinicaltrials.gov/ct2/show/NCT00533546?term=apcast&rank=1. 
41. 
Guo H, Wang Y, Singh I, Liu D, Fernández JA, Griffin JH, Chow N, Zlokovic BV. Species-
dependent neuroprotection by activated protein C mutants with reduced anticoagulant 
activity. J Neurochem. 2009;109(1):116-124. 
42. 
Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV. Differential 
neuroprotection and risk for bleeding from activated protein C with varying degrees of 
anticoagulant activity. Stroke. 2009;40(5):1864-1869. 
43. 
Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Copp M, Zlokovic BV. An Activated 
Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window 
of Tissue Plasminogen Activator for Ischemic Stroke in Rodents. Stroke. 2012;43. 
44. 
Wang Y, Zhao Z, Chow N, Rajput PS, Griffin J, Lyden P, et al. An activated protein C 
analog protects from ischemic stroke and extends the therapeutic window of tPA in aged 
female mice and hypertensive rats. Stroke. 2013 44(12):3529-3536. 
45. 
Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández JA, Chow N, Griffin JH, Zlokovic 
BV. Neuroprotective activities of activated protein C mutant with reduced anticoagulant 
activity. Eur J Neurosci. 2009;29(6):1119-1130. 
46. 
Walker CT, Marky AH, Petraglia AL, Ali T, Chow N, Zlokovic BV. Activated protein C 
analog with reduced anticoagulant activity improves functional recovery and reduces 
bleeding risk following controlled cortical impact. Brain Res. 2010;1347:125-131. 
47. 
Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thiyagarajan M, Deane R, 
Fernandez JA, Lane S, Zlokovic AB, Liu T, Griffin JH, Chow N, Castellino FJ, Stojanovic 
K, Cleveland DW, Zlokovic BV. Activated protein C therapy slows ALS-like disease in 
mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin 
Invest. 2009;119(11):3437-3449. 
48. 
Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, and Seifried E. 
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute 
myocardial infarction. J Am Coll Cardiol. 1992;19:1071-1075. 
49. 
Hesse K, Fulton RL, Abdul-Rahim AH, Lees KR, VISTA Collaborators. Characteristic 
adverse events and their incidence among patients participating in acute ischemic stroke 
trials. Stroke. 2014;45(9):2677-2682. 
50. 
Perry L., Love C. P. Screening for dysphagia and aspiration in acute stroke: a systematic 
review. Dysphagia. Winter 2001;16(1):7-18. 
51. 
Hilker R., Poetter C., Findeisen N., et al. Nosocomial pneumonia after acute stroke: 
implications for neurological intensive care medicine. Stroke. Apr 2003;34(4):975-981. 
52. 
Indredavik B., Rohweder G., Naalsund E., Lydersen S. Medical complications in a 
comprehensive stroke unit and an early supported discharge service. Stroke. Feb 
2008;39(2):414-420. 
53. 
Rocco A., Pasquini M., Cecconi E., et al. Monitoring after the acute stage of stroke: a 
prospective study. Stroke. Apr 2007;38(4):1225-1228. 
54. 
van de Beek Diederik, Wijdicks Eelco F. M., Vermeij Frederique H., et al. Preventive 
Antibiotics for Infections in Acute Stroke: A Systematic Review and Meta-analysis. Arch 
Neurol. September 1, 2009 2009;66(9):1076-1081. 

ZZ-3K3A-201 
Version 8.1 Final 
Version date 7-Oct-2016 
Page 81 of 81 
55. 
O'Quigley J, Pepe M, Fisher L. Continual Reassessment Method: A Practical Design for 
Phase 1 Clinical Trials in Cancer. Biometrics. 1990;46:33-48. 
56. 
Kimura K, Aoki J, Shibazaki K, Saji N, Uemura J, Sakamoto Y. New Appearance of 
Extraischemic Microbleeds on T2*-Weighted Magnetic Resonance Imaging 24 Hours 
After Tissue-type Plasminogen Activator Administration. Stroke. 2013;44:epub. 
57. 
Derex L, Nighoghossian N, Hermier M, Adeleine P, Philippeau F, Honnorat J, et al. 
Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. 
Cerebrovasc Dis. 2004;17:238-241. 
58. 
Harada M, Morita N, Uno M, Satomi J, Izumi Y, Asanuma K, et al. Incidence and clinical 
correlation of intracranial hemorrhages observed by 3-tesla gradient echo T(2)*-weighted 
images following intravenous thrombolysis with recombinant tissue plasminogen 
activator. Cerebrovasc Dis. 2010;29:571-575. 
59. 
Shoamanesh A, Kwok CS, Lim PA, Benavente OR. Post thrombolysis intracranial 
hemorrhage risk of cerebral microbleeds in acute stroke patients: a systematic review 
and meta-analysis. Int J Stroke. 2013;8:348-356. 
60. 
Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM, et al. Comparison 
of MRI and CT for detection of acute intracerebral hemorrhage. Journal of the American 
Medical Association. 2004;292:1823. 
61. 
Fiehler J, Albers GW, Boulanger JM, Derex L, Gass A, Hjort N, et al. Bleeding risk 
analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-
weighted magnetic resonance imaging data from 570 patients. Stroke. 2007;38:2738-
2744. 
62. 
Cheng AL, Batool S, McCreary CR, Lauzon ML, Frayne R, Goyal M, Smith EE. 
Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo 
MRI for detecting microbleeds. Stroke. 2013;44(10):2782-2786. 
63. 
Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV. An Activated 
Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window 
of Tissue Plasminogen Activator for Ischemic Stroke in Rodents. Stroke. 
2012;43(9):2444-2449.